

## Appendix Table S2

**List of records excluded during screening and data extraction.**

	<b>Author</b>	<b>Year</b>	<b>Title</b>
1	Abdalla, A., N. Byrne, R. Conway, T. Walsh, G. Mannion, M. Hanly, M. O'Sullivan, A. M. Curran and J. J. Carey	2017	Long-term safety and efficacy of biosimilar infliximab among patients with
2	Achmat, Z.	2002	The XIV International AIDS Conference. Treatment access as a human rig
3	Adams, E. R., G. J. Schoone, A. F. Ageed, S. E. Safi and H. D. Schallig	2010	Development of a reverse transcriptase loop-mediated isothermal amplifica clinical samples
4	Adekola, T. A.	2020	Revisiting the public health implications of the United States-Mexico- Can
5	Agudelo, M., C. A. Rodriguez, C. A. Pelaez and O. Vesga	2014	Even apparently insignificant chemical deviations among bioequivalent ge meropenem
6	Agudelo, M., C. A. Rodriguez, A. F. Zuluaga and O. Vesga	2019	Nontherapeutic equivalence of a generic product of imipenem-cilastatin is (imipenem) than by its substandard amount of cilastatin
7	Agudelo, M. and O. Vesga	2012	Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and ph intravenous metronidazole
8	Ahmad, K.	2001	Brazil and USA at loggerheads over production of generic antiretrovirals
9	Al Ani, N. A., F. I. Gorial, S. Al-Sulaiti, J. A. Humadi, N. I. Awadh, M. Mounir, Y. E. Dershabay, H. Jones and N. Sunna	2019	Review of biologics, biosimilars, and intended copies in rheumatology, and
10	Albach, C. A., R. Wagland and K. J. Hunt	2018	Cross-cultural adaptation and measurement properties of generic and cance patients in Brazil: a systematic review
11	Alkhafaji, A. A., L. Trinquart, G. Baron, M. Desvarieux and P. Ravaud	2012	Impact of evergreening on patients and health insurance: a meta analysis ar
12	Allavena, C., C. Jacomet, B. Pereira, L. Morand-Joubert, H. Bagheri, L. Cotte, R. Garaffo, L. Gerbaud and P. Dellamonica	2014	Acceptability and confidence in antiretroviral generics of physicians and H
13	Almeida, Phrf, T. B. C. Silva, F. de Assis Acurcio, A. A. Guerra Júnior, V. E. Araújo, L. M. Diniz, B. Godman, A. M. Almeida and J. Alvares	2018	Quality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin An Policy Implications
14	Alten, R., B. Batko, T. Hala, H. Kameda, S. C. Radominski, V. Tseluyko, G. Babic, C. Cronenberger, S. Hackley, M. Rehman, O. von Richter, M. Zhang and S. Cohen	2019	Randomised, double-blind, phase III study comparing the infliximab biosim immunogenicity from week 30 to week 54
15	Amariles, P., J. Galindo, H. F. Mueses-Marín and C. Castañeda	2019	[Effectiveness and safety of generic version of lamivudine/tenofovir and ef label, phase IV study in Cali-Colombia, 2012-2014]
16	Angalakuditi, M. and N. Angalakuditi	2011	A comprehensive review of the literature on epilepsy in selected countries
17	Antunes, J. E., M. P. Freitas and R. Rittner	2008	Bioactivities of a series of phosphodiesterase type 5 (PDE-5) inhibitors as
18	Araya, I., G. Fasce, E. Núñez, J. L. Opazo, E. Saez, V. Hurtado, S. Contreras and L. A. Quiñones	2015	A Non-inferiority Pilot Study Comparing the Clinical Efficacy and Safety
19	Arifeen, S. E., J. Bryce, E. Gouws, A. H. Baqui, R. E. Black, D. M. Hoque, E. K. Chowdhury, M. Yunus, N. Begum, T. Akter and A. Siddique	2005	Quality of care for under-fives in first-level health facilities in one district
20	Arredondo, A.	2008	Out-of-pocket costs to users: medicine options for hypertension
21	Arteaga, E. and P. Villaseca	1998	Pharmacokinetic comparison between Conpremin (Premarin) and a generi
22	Ascef, B. O., M. O. Almeida, A. C. de Medeiros Ribeiro, D. C. O. Andrade, H. A. de Oliveira Júnior, T. V. Pereira and P. C. de Soárez	2021	Equivalence and switching between biosimilars and reference molecules in
23	Ascef, B. O., A. C. F. Lopes and P. C. de Soárez	2020	Health technology assessment of biosimilars worldwide: a scoping review
24	Ashraf, H.	2001	USA and Brazil end dispute over essential drugs
25	Association Accompagnement pour un Internet en Médecine et Santé au Service des, Usagers	2014	CARNet : Self-Monitoring and Co-driving in Rheumatology With Internet
26	Avila-Portillo, L. M., F. Aristizabal, S. Perdomo, A. Riveros, B. Ospino, J. P. Avila, M. Butti and M. C. Abba	2020	Comparative Analysis of the Biosimilar and Innovative G-CSF Modulated
27	Azevedo, V., B. Hassett, J. E. Fonseca, T. Atsumi, J. Coindreau, I. Jacobs, E. Mahgoub, J. O'Brien, E. Singh, S. Vicik and B. Fitzpatrick	2016	Differentiating biosimilarity and comparability in biotherapeutics
28	Azevedo, V. F., N. Galli, A. Kleinfelder, J. D'Ippolito and P. C. Urbano	2015	Etanercept biosimilars
29	Azevedo, V. F., I. A. Kos and L. Ariello	2017	The Experience with Biosimilars of Infliximab in Rheumatic Diseases
30	Baer Ii, W. H., A. Maini and I. Jacobs	2014	Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin

	Journal
h inflammatory arthritis switched from reference product	Open Access Rheumatol
ht	Posit Aware
ation (LAMP) assay for the sensitive detection of Leishmania parasites in	The American journal of tropical medicine and hygiene
ada agreement	Global Health
neric antibiotics can lead to therapeutic nonequivalence: the case of	Antimicrob Agents Chemother
caused more by chemical instability of the active pharmaceutical ingredient	PLoS One
armacodynamic identities: true bioequivalence of a generic product of	Antimicrob Agents Chemother
	Lancet
d current practice in Iraq	Open Access Rheumatol
er-related patient-reported outcome measures (PROMs) for use with cancer	Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
nd reimbursement cost analysis of citalopram/escitalopram antidepressants	BMC medicine
HIV-infected patients in France	Journal of the International AIDS Society
alog Glargine Compared with NPH Insulin: A Systematic Review and	The patient
milar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and	RMD Open
favirenz in treatment naïve HIV-infected patients: a nonrandomized, open-	Rev Chilena Infectol
in emerging markets	Neuropsychiatric disease and treatment
modelled by MIA-QSAR	Eur J Med Chem
of Generic Wide-spectrum Antibiotic Use in Septic Oncology Patients	Drug Res (Stuttg)
of Bangladesh	Bulletin of the World Health Organization
	Am J Hypertens
e preparation of conjugated estrogens	Climacteric
n rheumatoid arthritis: protocol for a systematic review and meta-analysis	Syst Rev
	Health Res Policy Syst
	Lancet
: Rheumatoid Arthritis Cohort (Usual Care Study)	<a href="https://clinicaltrials.gov">clinicaltrials.gov</a>
Pathways on Umbilical Cord Blood-Derived Mononuclear Cells	Bioinform Biol Insights
	Clin Rheumatol
	Rheumatol Int
	Curr Pharm Des
's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey	Pharmaceuticals (Basel)

Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	<b>Author</b>	<b>Year</b>	<b>Title</b>
31	Bagechi, S.	2015	Campaigners challenge patent applications for hepatitis C drug in five countries
32	Baker, B. K.	2016	Trans-Pacific Partnership Provisions in Intellectual Property, Transparency and Trade Dispute Resolution: Elsewhere
33	Baracho, N. C., G. D. Arruda, L. J. Alves, M. F. Carneiro, M. T. Siqueira, H. G. Arango and J. Marcos dos Reis	2008	Bioequivalence study of four different trademarks of enalapril maleate in solid oral dosage forms
34	Bardach, A., A. Ciapponi, S. Garcia-Marti, D. Glujovsky, A. Mazzoni, A. Fayad, R. E. Colindres and A. Gentile	2011	Epidemiology of acute otitis media in children of Latin America and the Caribbean
35	Bardach, A. E., L. Rey-Ares, M. Calderon Cahua, A. Ciapponi, M. L. Cafferata, G. Cormick and A. Gentile	2017	Burden of Culture-Confirmed Pediatric Pneumococcal Pneumonia in Latin America
36	Barr, P. J., I. Scholl, P. Bravo, M. J. Faber, G. Elwyn and M. McAllister	2015	Assessment of patient empowerment - a systematic review of measures
37	Barr, R. D., A. Gonzalez, M. Longchong, W. Furlong, M. P. Vizcaino, J. Horsman, L. Fu and L. Castillo	2001	Health status and health-related quality of life in survivors of cancer in Chile
38	Barrientos-Astigarraga, R. E.	2011	Bioanalysis in Latin America: where are we and where are we going?
39	Bas, T. G. and C. Olier Castillo	2016	Biosimilars in Developed and Developing East and Southeast Asian Countries: A Regulatory Assessment
40	Bbosa, Godfrey S., Geoff Wong, David B. Kyegombe and Jasper Ogwali-Okeng	2014	Effects of intervention measures on irrational antibiotics/antibacterial drug use in Uganda
41	Beall, R. F., L. Hardcastle, F. Clement and A. Hollis	2019	How will recent trade agreements that extend market protections for brand-name drugs affect patients in Canada?
42	Beauchet, O., L. Cp, M. Montero-Odasso, C. Annweiler and V. Allali	2015	Anti-dementia drugs-related changes in gait performance while single and dual task walking
43	Bednarek, Z., J. M. Doremus and S. S. Stith	2022	U.S. cannabis laws projected to cost generic and brand pharmaceutical firms \$1.5 billion
44	Bérard, A., F. Abbas-Chorfa, B. Kassai, T. Vial, K. A. Nguyen, O. Sheehy and A. M. Schott	2019	The French Pregnancy Cohort: Medication use during pregnancy in the French population
45	Bermúdez, H., E. Rojas, L. Garcia, P. Desjeux, J. C. Dujardin, M. Boelaert and F. Chappuis	2006	Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate in the treatment of visceral leishmaniasis in Secure Park, Bolivia
46	Bertoldi, A. D., P. S. Arrais, N. U. Tavares, L. R. Ramos, V. L. Luiza, S. S. Mengue, T. D. Dal-Pizzol, M. R. Farias and M. A. Oliveira	2016	Use of generic medicines by the Brazilian population: an evaluation of PN
47	Bertoldi, A. D., L. A. Chaves, D. Ross-Degnan, V. L. Luiza, I. C. M. Emmerick, R. M. D. Silva and M. R. Campos	2019	Brazilian generics market change after Farmácia Popular program
48	Bertoldi, A. D., A. P. Helfer, A. L. Camargo, N. U. Tavares and P. Kanavos	2012	Is the Brazilian pharmaceutical policy ensuring population access to essential medicines?
49	Bevilacqua, G., M. R. Farias and C. R. Blatt	2011	Procurement of generic medicines in a medium size municipality
50	Bianchi, C. M., F. Mariotti, A. Lluch, C. Journet, Y. Stehr, H. Beaussier, J. Fournier, S. Dervaux, D. Cohen-Tanuggi, E. Reulet, E. O. Verger, E. Azria and J. F. Huneau	2020	Computer-based tailored dietary counselling improves the nutrient adequacy of diets in French adults
51	Blakely, T., J. Thompson, L. Bablani, P. Andersen, D. Ait Ouakrim, N. Carvalho, P. Abraham, M. A. Boujaoude, A. Katar, E. Akpan, N. Wilson and M. Stevenson	2021	Association of Simulated COVID-19 Policy Responses for Social Restriction in Australia
52	Blauvelt, A., L. Puig, S. Chimenti, R. Vender, M. Rajagopalan, R. Romiti, L. Skov, C. Zachariae, H. Young, E. Prens, A. Cohen, J. van der Walt and J. J. Wu	2017	Biosimilars for psoriasis: clinical studies to determine similarity
53	Bonetti, L., A. Tolotti, G. Anderson, T. Nania, C. Vignaduzzo, D. Sari and S. Barello	2022	Nursing interventions to promote patient engagement in cancer care: A systematic review
54	Borges Dos Santos, M. A., L. L. Dos Santos Dias, C. D. B. Santos Pinto, R. M. da Silva and C. G. S. Osorio-de-Castro	2019	Factors influencing pharmaceutical pricing - a scoping review of academic literature
55	Bórquez, A., J. V. Guanira, P. Revill, P. Caballero, A. Silva-Santisteban, S. Kelly, X. Salazar, P. Bracamonte, P. Minaya, T. B. Hallett and C. F. Cáceres	2019	The impact and cost-effectiveness of combined HIV prevention scenarios: a modelling study
56	Borrescio-Higa, F.	2015	Can Walmart make us healthier? Prescription drug prices and health care utilization
57	Boudreau, F., G. Godin and P. Poirier	2011	Effectiveness of a computer-tailored print-based physical activity intervention
58	Bouhnik, A. D., K. N'Diaye, D. G. Evans, H. Harris, A. Tibben, C. van Asperen, J. Schmidtke, I. Nippert, J. Mancini and C. Julian-Reynier	2017	Validation of a scale for assessing attitudes towards outcomes of genetic carrier testing
59	Bourdel, N., P. Chauvet, V. Billone, G. Douridas, A. Fauconnier, L. Gerbaud and M. Canis	2019	Systematic review of quality of life measures in patients with endometriosis
60	Bourget, N., A. Deblock-Bellamy, A. K. Blanchette and C. S. Batcho	2018	Use and psychometric properties of the Reintegration to Normal Living Index

	Journal
ountries	Bmj
, and Investment Chapters Threaten Access to Medicines in the US and	PLoS Med
spontaneously hypertensive rats	Acta Cir Bras
Caribbean: a systematic review and meta-analysis	International journal of pediatric otorhinolaryngology
Latin America and the Caribbean: A Systematic Review and Meta-Analysis	Value in health regional issues
	PloS one
Childhood in Latin America: a MISPHO feasibility study	International journal of oncology
	Bioanalysis
ountries: Japan, South Korea, and Malaysia-Overview, Evolution, and	Biomed Res Int
use in developing countries: A systematic review	Health
Generic-name prescription pharmaceuticals impact expenditures and generic access	Health Policy
Individual tasking in patients with Alzheimer disease: a meta-analysis	Current Alzheimer research
ns billions	PLoS One
rench population	PloS one
ine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro	Ann Trop Med Parasitol
AUM 2014	Rev Saude Publica
	Rev Saude Publica
cial medicines?	Global Health
	Rev Saude Publica
ey of the diet of French pregnant women: a randomised controlled trial	The British journal of nutrition
ons and Lockdowns With Health-Adjusted Life-Years and Costs in Victoria,	JAMA health forum
	Br J Dermatol
tematic review	International journal of nursing studies
literature in health science	J Pharm Policy Pract
among transgender women sex-workers in Lima, Peru: a mathematical	The Lancet. Public health
tilization	J Health Econ
ion among French Canadians with type 2 diabetes in a real-life setting	Health education research
ancer testing among primary care providers and breast specialists	PloS one
s	PloS one
dex in rehabilitation: A systematic review	Annals of physical and rehabilitation medicine

Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	<b>Author</b>	<b>Year</b>	<b>Title</b>
61	Bousquet, J., A. Flahault, O. Vandenplas, J. Ameille, J. J. Duron, C. Pecquet, K. Chevré and I. Annesi-Maesano	2006	Natural rubber latex allergy among health care workers: a systematic review
62	Bovis, F., A. Consolaro, A. Pistorio, M. Garrone, S. Scala, E. Patrone, M. Rinaldi, L. Villa, A. Martini, A. Ravelli and N. Ruperto	2018	Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Questionnaire in 52 countries: review of the general methodology
63	Boyer, S., L. March, C. Kouanfack, G. Laborde-Balen, P. Marino, A. F. Aghokeng, E. Mpoudi-Ngole, S. Koulla-Shiro, E. Delaporte, M. P. Carrieri, B. Spire, C. Laurent, J. P. Moatti and Anrs Esther Study Group Stratall	2013	Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis
64	Braddy, A. C., B. M. Davit, E. M. Stier and D. P. Conner	2015	Survey of international regulatory bioequivalence recommendations for ap
65	Bregonzio, C., S. Eyal, F. Erdő and M. F. Pérez	2022	Editorial: Women in drug metabolism and transport: 2021
66	Brownlee, W. J., C. Wolf, H. P. Hartung, T. Dingeremann, N. Anshasi, R. A. Clark, M. Trojano, K. Selmaj, B. M. Uitdehaag, C. Tur, J. Wuerfel, G. Dallmann, J. Witte, M. Sintzel, O. Bobrovnikova and J. A. Cohen	2022	Use of follow-on disease-modifying treatments for multiple sclerosis: Con
67	Brunner, H. I., C. Abud-Mendoza, M. Mori, C. A. Pilkington, R. Syed, S. Takei, D. O. Viola, R. A. Furie, S. Navarra, F. Zhang, D. L. Bass, G. Eriksson, A. E. Hammer, B. N. Ji, M. Okily, D. A. Roth, H. Quasny and N. Ruperto	2021	Efficacy and safety of belimumab in paediatric and adult patients with syst
68	Brunner, H. I., C. Abud-Mendoza, D. O. Viola, I. Calvo Penades, D. Levy, J. Anton, J. E. Calderon, V. G. Chasnyk, M. A. Ferrandiz, V. Keltsev, M. E. Paz Gastanaga, M. Shishov, A. L. Boteanu, M. Henrickson, D. Bass, K. Clark, A. Hammer, B. N. Ji, A. Nino, D. A. Roth, H. Struemper, M. L. Wang, A. Martini, D. Lovell and N. Ruperto	2020	Safety and efficacy of intravenous belimumab in children with systemic lup
69	Brunner, H. I., N. Ruperto, N. Tzaribachev, G. Horneff, V. G. Chasnyk, V. Panaviene, C. Abud-Mendoza, A. Reiff, E. Alexeeva, N. Rubio-Pérez, V. Keltsev, D. J. Kingsbury, M. Del Rocio Maldonado Velázquez, I. Nikishina, E. D. Silverman, R. Joos, E. Smolewska, M. Bandeira, K. Minden, A. van Royen-Kerkhof, W. Emminger, I. Foeldvari, B. R. Lauwerys, F. Sztajnbock, K. E. Gilmer, Z. Xu, J. H. Leu, L. Kim, S. L. Lamberth, M. J. Loza, D. J. Lovell and A. Martini	2018	Subcutaneous golimumab for children with active polyarticular-course juv
70	Bueno, C. S., A. C. Moreira and K. R. Oliveira	2012	[Cost of drugs used to treat cardiovascular disease in Brazil]
71	Burgos-Vargas, R., L. J. Catoggio, C. Galarza-Maldonado, K. Ostojich and M. H. Cardiel	2013	Current therapies in rheumatoid arthritis: a Latin American perspective
72	Butler, D.	2004	Brands in peril as Brazil strives to keep AIDS drugs free
73	Caballero-Uribe, C. V., V. F. Azevedo, E. R. Soriano, C. Pineda, C. Galarza-Maldonado, I. A. Kos and O. C. Jimenez	2020	Report on the Second PANLAR Review Course in Rheumatology: Biosim
74	Cafferata, M. L., A. Bardach, L. Rey-Ares, A. Alcaraz, G. Cormick, L. Gibbons, M. Romano, S. Cesaroni and S. Ruvinsky	2013	Dengue Epidemiology and Burden of Disease in Latin America and the Ca
75	Calderón, M., V. Brito, A. Alcaraz, L. Rey-Ares, F. Augustovski, S. García-Martí, A. Bardach, A. Ciapponi, A. López and A. Pichón-Riviere	2018	Endovascular Repair for Aortic Aneurysm: Overview of the evidence in the
76	Camara, S., D. Zucman, M. Vasse, A. Goudjo, E. Guillard and G. Peytavin	2015	[Lack of bioavailability of generic lopinavir/ritonavir not prequalified by V
77	Cameron, D., M. J. Piccart-Gebhart, R. D. Gelber, M. Procter, A. Goldhirsch, E. de Azambuja, G. Castro, Jr., M. Untch, I. Smith, L. Gianni, J. Baselga, N. Al-Sakaff, S. Lauer, E. McFadden, B. Leyland-Jones, R. Bell, M. Dowsett and C. Jackisch	2017	11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2- (HERA) trial
78	Candelaria, M. and A. Dueñas-Gonzalez	2021	Rituximab in combination with cyclophosphamide, doxorubicin, vincristin
79	Candelaria, M., D. Gonzalez, F. J. Fernández Gómez, A. Paravisini, A. Del Campo García, L. Pérez, B. Miguel-Lillo and S. Millán	2018	Comparative assessment of pharmacokinetics, and pharmacodynamics betw
80	Candelaria, M., D. E. González, M. T. Delamain, D. O. Bär, S. K. Beniwal, L. Dasappa, D. H. Flores, J. Querol, T. S. Guan, O. N. Lipatov, E. M. Volodicheva, M. Patel, S. R. Safaei Nodehi, L. Fogliatto, A. Paravisini and L. Perez Diaz	2019	Rituximab biosimilar RTX83 versus reference rituximab in combination
81	Cárdenas, K. P. C., J. E. R. Velázquez, J. J. O. Escobar, J. Chirinos and M. Pendela	2020	Bioequivalence and Tolerability of Ambrisentan: A Pharmacokinetic Study
82	Cárdenas, K. P. C., J. E. R. Velázquez, J. J. O. Escobar, J. Chirinos and M. Pendela	2020	Bioequivalence and Tolerability of Ambrisentan: A Pharmacokinetic Study
83	Carlos, F., J. Ramírez-Gómez, H. Dueñas, R. M. Galindo-Suárez and E. Ramos	2012	Economic evaluation of duloxetine as a first-line treatment for painful diab

	Journal
ow of the evidence	The Journal of allergy and clinical immunology
ritis Multidimensional Assessment Report (JAMAR) in 54 languages across	Rheumatol Int
us clinical monitoring alone for antiretroviral therapy in low-resource	The Lancet. Infectious diseases
proval of generic topical dermatological drug products	Aaps j Front Pharmacol
sensus recommendations	Mult Scler
emic lupus erythematosus: an across-study comparison	RMD Open
pus erythematosus: results from a randomised, placebo-controlled trial	Ann Rheum Dis
enile idiopathic arthritis: results of a multicentre, double-blind, randomised-	Ann Rheum Dis
	Rev Panam Salud Publica
	Reumatol Clin
	Nature
ilars Update	J Clin Rheumatol
ibbean: A Systematic Review of the Literature and Meta-Analysis	Value in Health Regional Issues
e world and its application in Latin America	Value in health regional issues
WHO marketed in Africa (Congo Brazzaville)]	Bulletin de la Societe de pathologie exotique (1990)
positive early breast cancer: final analysis of the HERceptin Adjuvant	Lancet
e, and prednisone (R-CHOP) in diffuse large B-cell lymphoma	Ther Adv Hematol
ween RTX83™, a rituximab biosimilar, and rituximab in diffuse large B-	Cancer Chemother Pharmacol
with CHOP as first-line treatment for diffuse large B-cell lymphoma: a	Leuk Lymphoma
in Mexican Healthy Male Subjects	Eur J Drug Metab Pharmacokinet
in Mexican Healthy Male Subjects	European journal of drug metabolism and pharmacokinetics
abetic peripheral neuropathy in Mexico	Journal of medical economics

Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	Author	Year	Title
84	Caro-Vega, Y., P. F. Belaunzarán-Zamudio, B. E. Crabtree-Ramírez, B. E. Shepherd, B. Grinsztejn, M. Wolff, J. W. Pape, D. Padgett, E. Gotuzzo, C. C. McGowan and J. G. Sierra-Madero	2018	Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based South America
85	Carrá, A., M. A. Macías Islas, A. Tarulla, D. B. Bichuetti, A. Finkelsztejn, Y. D. Fragoso, R. Arcega-Revilla, C. Cárcamo Rodríguez, J. C. Durán, J. G. Bonitto, R. León, C. Oehninger Gatti, G. Orozco and D. Vizcarra Escobar	2015	Biological and nonbiological complex drugs for multiple sclerosis in Latin
86	Carrol, L. Gamble, Ekwaru John Paul and O. ter Kuile Feiko	2006	Insecticide-treated nets for preventing malaria in pregnancy
87	Cartagena, R. G. and A. Attaran	2009	A study of pharmaceutical data exclusivity laws in Latin America: is access
88	Carvalho, M. C., H. Accioly Júnior and F. N. Raffin	2006	[Social representations of generic drugs by consumers from Natal, Rio Gra
89	Casella, I. B. and P. Puech-Leão	2015	Generic versus branded enoxaparin in prophylaxis and treatment of vein th
90	Castañeda-Hernández, G., R. González-Ramírez, J. Kay and M. A. Scheinberg	2015	Biosimilars in rheumatology: what the clinician should know
91	Castañeda-Hernández, G., Z. Szekanez, E. Mysler, V. F. Azevedo, R. Guzman, M. Gutierrez, W. Rodríguez and D. Karateev	2014	Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russ
92	Castaneda-Cázares, J. P., J. Quistián-Galván, B. Torres-Alvarez, A. Torres-Ruvalcaba and B. Moncada	2001	[Antiinflammatory effect of a topical corticosteroid: known brand versus g
93	Castillo, G., A. Rossano-García, D. Gutiérrez, H. S. Diliz-Pérez and J. Córdova	2013	[Acute cellular rejection in a liver transplantation patient due to changing t
94	Cawthorne, P., N. Ford, J. Limpanant, N. Tienudom and W. Purahong	2007	WHO must defend patients' interests, not industry
95	Cerutti, M. L., A. Pesce, C. Bès and M. Seigelchifer	2019	Physicochemical and Biological Characterization of RTX83, a New Ritux
96	Chadwick, L., S. Zhao, E. Mysler and R. J. Moots	2018	Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthriti
97	Charoo, N. A., R. Cristofolletti and S. K. Kim	2017	Integrating biopharmaceutics risk assessment and in vivo absorption mode
98	Chassany, O., P. Marquis, B. Scherrer, N. W. Read, T. Finger, J. F. Bergmann, B. Fraitag, J. Geneve and C. Caulin	1999	Validation of a specific quality of life questionnaire for functional digestiv
99	Chavez Arana, C., C. Catroppa, G. Yáñez-Télez, B. Prieto-Corona, M. A. de León, A. García, R. Gómez-Raygoza, S. J. C. Hearps and V. Anderson	2020	A Parenting Program to Reduce Disruptive Behavior in Hispanic Children Mexico
100	Check, E.	2004	Generic drugs allowed in global trial of AIDS therapy
101	Chen, B., S. Nagai, J. O. Armitage, B. Witherspoon, C. Nabhan, A. C. Godwin, Y. T. Yang, A. Kommalapati, S. H. Tella, C. DeAngelis, D. W. Raisch, O. Sartor, W. J. Hrushesky, P. S. Ray, P. R. Yarnold, B. L. Love, L. B. Norris, K. Knopf, L. Bobolts, J. Riente, S. Luminari, R. C. Kane, S. Hoque and C. L. Bennett	2019	Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S.
102	Christenson, G.	2004	Mayo Clinic office visit. Acquiring your medicines safely
103	Coates, L. C., E. R. Soriano, N. Corp, H. Bertheussen, K. Callis Duffin, C. B. Campanholo, J. Chau, L. Eder, D. G. Fernández-Ávila, O. FitzGerald, A. Garg, D. D. Gladman, N. Goel, P. S. Helliwell, M. E. Husni, D. R. Jadon, A. Katz, D. Laheru, J. Latella, Y. Y. Leung, C. Lindsay, E. Lubrano, L. D. Mazzuocolo, P. J. Mease, D. O'Sullivan, A. Ogdie, W. Olsder, P. E. Palominos, L. Schick, I. Steinkoenig, M. de Wit, D. A. van der Windt and A. Kavanaugh	2022	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (G
104	Coelho Neto, J. and F. L. C. Lisboa	2017	ATR-FTIR characterization of generic brand-named and counterfeit silden
105	Cohen, A. D., J. J. Wu, L. Puig, S. Chimenti, R. Vender, M. Rajagopalan, R. Romiti, C. de la Cruz, L. Skov, C. Zachariae, H. S. Young, P. Foley, J. M. van der Walt, L. Naldi, E. P. Prens and A. Blauvelt	2017	Biosimilars for psoriasis: worldwide overview of regulatory guidelines, up
106	Cohen, J.	2000	AIDS meeting. Companies, donors pledge to close gap in AIDS treatment
107	Cohen, J.	2006	HIV/AIDS: Latin America & Caribbean. Brazil: ten years after
108	Cohen, J.	2007	AIDS drugs. Brazil, Thailand override big pharma patents
109	Cohen, S. B., R. Alten, H. Kameda, T. Hala, S. C. Radominski, M. I. Rehman, R. Palaparthi, K. Schumacher, S. Schmitt, S. Y. Hua, C. Ianos and K. L. Sewell	2018	A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) to severe active rheumatoid arthritis despite methotrexate therapy
110	Cohen, S. B., R. Burgos-Vargas, P. Emery, B. Jin, C. Cronenberger and M. D. Vázquez-Abad	2018	Extension Study of PF-05280586, a Potential Rituximab Biosimilar, Versus

	Journal
Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and	Open forum infectious diseases
America: regulations and risk management	Expert Rev Neurother
	Cochrane database of systematic reviews (Online)
s to affordable medicine threatened?	Health Law J
de do Norte, Brazil]	Cad Saude Publica
rombosis	Rev Assoc Med Bras (1992)
	RMD Open
ia, and India: innovators, biosimilars, and intended copies	Joint Bone Spine
generic drug]	Gac Med Mex
the brand of a generic immunosuppressant]	Rev Gastroenterol Mex
	Lancet
uximab Biosimilar	BioDrugs
is	Curr Rheumatol Rep
l in formulation development of BCS class I drug using the QbD approach	Drug Dev Ind Pharm
e disorders	Gut
with Acquired Brain Injury: A Randomized Controlled Trial Conducted in	Developmental neurorehabilitation
	Nature
, the European Union, Japan, and Canada	Oncologist
	Mayo Clin Womens Healthsource
RAPPA): updated treatment recommendations for psoriatic arthritis 2021	Nat Rev Rheumatol
afil- and tadalafil-based tablets found on the Brazilian market	Sci Justice
take and implications for dermatology clinical practice	Br J Dermatol
	Science
	Science
	Science
imab biosimilar) and infliximab reference product for treatment of moderate	Arthritis Res Ther
s Rituximab in Subjects With Active Rheumatoid Arthritis	Arthritis Care Res (Hoboken)



Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	<b>Author</b>	<b>Year</b>	<b>Title</b>
111	Cohen, S. B., S. C. Radominski, H. Kameda, A. J. Kivitz, M. Tee, C. Cronenberger, M. Zhang, S. Hackley, M. I. Rehman, O. von Richter and R. Alten	2020	Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) E After Switching from Reference IFX or Continuing Biosimilar Therapy: W
112	Coignard-Biehler, H., C. Rapp, J. M. Chapplain, B. Hoen, D. Che, P. Berthelot, F. Cazenave-Roblot, C. Rabaud, P. Brouqui, C. Leport and Spilf-Coreb Emergences group	2018	The French Infectious Diseases Society's readiness and response to epidem respiratory syndrome coronavirus and Ebola virus disease alerts
113	Colombo, T. E., D. Vedovello, C. C. Pacca-Mazaro, A. Mondini, J. P. Araújo, E. Cabrera, J. C. Lopes, I. N. Penha Dos Santos, A. F. Negri Reis, F. R. Costa, L. E. A. Antônio Cruz, J. Ferreira, E. S. de Oliveira Rocha, E. G. Kroon, R. V. de Moraes Bronzoni, N. Vasilakis and M. L. Nogueira	2016	Dengue virus surveillance: Detection of DENV-4 in the city of São José do
114	Correale, J.	2017	Follow-on products for treatment of multiple sclerosis in Latin America: A
115	Correale, J., E. Chiquete, A. Boyko, R. G. Beran, J. B. Strauch, S. Milojevic and N. Frider	2016	Clinical implications for substandard, nonproprietary medicines in multipl
116	Correia, L. F. L., B. R. C. Alves, Ritp Batista, P. Mermillod and J. M. G. Souza-Fabjan	2021	Antifreeze proteins for low-temperature preservation in reproductive medi
117	Costagliola, D., V. Potard, S. Lang, S. Abgrall, C. Duvivier, H. Fischer, V. Joly, J. M. Lacombe, M. A. Valantin, M. Mary-Krause and S. Rozenberg	2019	Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individua HIV (FHDH-ANRS CO4)
118	Crager, S. E., E. Guillen and M. Price	2009	University contributions to the HPV vaccine and implications for access to university technology transfer policy
119	Cristiano, E., L. Patrucco, J. I. Rojas, F. Cáceres, A. Carrá, J. Correale, O. Garcea, L. Gold, J. Tessler and M. Kremenchutzky	2009	Prevalence of multiple sclerosis in Buenos Aires, Argentina using the captu
120	Cristofolletti, R., S. Schmidt and A. Diniz	2018	Non-Procrustean pathways for complex generic drugs development
121	Cruz, T. A., M. B. Pinho and L. R. Castilho	2020	Evaluation of different IRES-mediated tricistronic plasmid designs for exp
122	Cuello, H. A., V. I. Segatori, M. Alberto, A. Pesce, D. F. Alonso and M. R. Gabri	2016	Comparability of Antibody-Mediated Cell Killing Activity Between a Prop
123	Cui, C., T. Liu, T. Chen, J. Lu, I. Casaren, D. B. Lima, P. C. Carvalho, A. Beuve and H. Li	2019	Comprehensive identification of protein disulfide bonds with pepsin/trypsi
124	Czepielewski, M. A., Q. Garret, S. A. C. Vencio, N. Rassi, M. S. Faria, C. C. P. Senn, M. D. Bronstein, Mjag Cerqueira, A. C. L. Neves, A. M. Spinola-Castro, M. P. R. Cunha, N. R. Leite, G. E. Wassermann, M. C. Alegria, O. Toffoletto, J. Afiune, R. Baradelli, D. G. Rodrigues and M. Scharf	2021	Switching from originator recombinant growth hormone (Genotropin™) to inferiority, extension trial
125	Czepielewski, M. A., Q. Garret, S. A. C. Vencio, N. Rassi, J. S. Felicio, M. S. Faria, C. C. P. Senn, M. D. Bronstein, Mjag Cerqueira, A. C. L. Neves, J. A. Sgarbi, A. M. Spinola-Castro, M. P. R. Cunha, F. Bandeira, O. Toffoletto, J. Afiune, R. Baradelli, D. G. Rodrigues and M. Scharf	2019	Efficacy and safety of a biosimilar recombinant human growth hormone (r hormone deficiency (CERES study): A randomized, multicentric, investiga
126	da Fonseca, E. M., K. Shadlen and F. I. Bastos	2019	Brazil's Fight against Hepatitis C - Universalism, Local Production, and Pa
127	D'Amico, F., L. Pouillon, M. Argollo, A. Hart, G. Fiorino, E. Vegni, S. Radice, D. Gilardi, M. Fazio, S. Leone, S. Bonovas, F. Magro, S. Danese and L. Peyrin-Biroulet	2020	Multidisciplinary management of the nocebo effect in biosimilar-treated IF
128	Danzon, P. M. and M. F. Furukawa	2003	Prices and availability of pharmaceuticals: evidence from nine countries
129	Danzon, P. M. and M. F. Furukawa	2008	International prices and availability of pharmaceuticals in 2005
130	de Araújo, A. V. L., F. P. G. Ribeiro, T. Massetti, K. A. Potter-Baker, M. Cortes, E. B. Plow, T. D. da Silva, J. Tonks, R. Anghinah, F. H. Magalhães, F. Fregni and C. B. de Mello Monteiro	2020	Effectiveness of anodal transcranial direct current stimulation to improve r systematic review and meta-analysis
131	de Araujo, T. P., I. M. Fittipaldi, D. C. G. Bedor, M. L. Duarte, S. F. Cordery, R. H. Guy, M. B. Delgado-Charro, D. P. de Santana and L. B. Leal	2018	Topical bio(in)equivalence of metronidazole formulations in vivo
132	de Assis, M. R. and V. Pinto	2018	Strengths and weaknesses of the Brazilian regulation on biosimilars: A criti
133	de Freitas Silva, M., S. G. Schramm, E. K. Kano, E. E. Koono, J. L. Manfio, V. Porta and C. H. dos Reis Serra	2012	Metronidazole immediate release formulations: a fasting randomized open
134	de Godoy Bertanha, M. L. and F. R. Lourenço	2021	Risk of false pharmaceutical equivalence (non-equivalence) decisions due
135	de la Cruz, C., A. V. de Carvalho, G. L. Dorantes, A. M. Londoño Garcia, C. Gonzalez, M. Maskin, N. Podoswa, J. S. Redfern, F. Valenzuela, J. van der Walt and R. Romiti	2017	Biosimilars in psoriasis: Clinical practice and regulatory perspectives in La
136	de Mattos, L. I. S., F. K. Ferraris, T. S. C. Machado, T. M. de Brito, A. S. Chaves, H. M. Pereira, D. P. Pinto, D. M. D. da Silva and F. C. Amendoeira	2016	Post-marketing surveillance of generic amoxicillin using a microbiologica

	Journal
Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial	BioDrugs
nic or biological risk-the current situation following the Middle East	Medecine et maladies infectieuses
o Rio Preto, SP, Brazil	Acta tropica
n update	J Neurol Sci
e sclerosis: focus on fingolimod	Drug Des Devel Ther
icine: A systematic review over the last three decades	Theriogenology
ls: A Case-Control Study Nested Within the French Hospital Database on	Journal of acquired immune deficiency syndromes (1999)
o vaccines in developing countries: addressing materials and know-how in	Am J Law Med
ure-recapture method	European journal of neurology : the official journal of the European Federation of Neurological Societies
	Ther Deliv
pression of an anti-PCSK9 biosimilar monoclonal antibody in CHO cells	Biotechnol Lett
posed Biosimilar RTX83 and the Originator Rituximab	BioDrugs
in digestion, Orbitrap HCD and Spectrum Identification Machine	J Proteomics
o biosimilar (CRISCY™): Results from a 6-month, multicentric, non-	Growth Horm IGF Res
-hGH Cristalia) compared with reference r-hGH in children with growth ator-blind, phase 3 trial	Growth Horm IGF Res
atents	N Engl J Med
BD patients: Results of a workshop from the NOCE-BIO consensus group	Dig Liver Dis
	Health Aff (Millwood)
	Health Aff (Millwood)
muscle strength and motor functionality after incomplete spinal cord injury: a	Spinal cord
	Int J Pharm
ical view of the regulatory requirements for biosimilars in Brazil	Ther Adv Musculoskelet Dis
-label crossover bioequivalence study in healthy volunteers	Arzneimittelforschung
to measurement uncertainty	J Pharm Biomed Anal
atin America	J Dermatol
l assay and pharmacokinetic approach in rats	Int J Antimicrob Agents

## Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	Author	Year	Title
137	De Oliveira, G. L., A. A. Guerra Júnior, B. Godman and F. A. Acurcio	2017	Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus
138	de Oliveira, L. H., M. C. Danovaro-Holliday, J. K. Andrus, A. M. de Fillipis, J. Gentsch, C. R. Matus, M. A. Widdowson and Network Rotavirus Surveillance	2009	Sentinel hospital surveillance for rotavirus in latin american and Caribbean
139	de Rivera, I. L., L. Amador, S. Mourra, Z. Li and S. Rasheed	1995	Geographical clustering of human T-cell lymphotropic virus type 1 infection
140	de Souza, R. M., J. A. Achcar, E. Z. Martinez and J. Mazucheli	2016	The use of asymmetric distributions in average bioequivalence
141	Degenhardt, L., A. J. Ferrari, B. Calabria, W. D. Hall, R. E. Norman, J. McGrath, A. D. Flaxman, R. E. Engell, G. D. Freedman, H. A. Whiteford and T. Vos	2013	The global epidemiology and contribution of cannabis use and dependence
142	Denduluri, N., M. R. Somerfield, M. Chavez-MacGregor, A. H. Comander, Z. Dayao, A. Eisen, R. A. Freedman, R. Gopalakrishnan, S. L. Graff, M. J. Hassett, T. A. King, G. H. Lyman, G. R. Maupin, R. Nunes, C. L. Perkins, M. L. Telli, M. E. Trudeau, A. C. Wolff and S. H. Giordano	2021	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early-Stage Breast Cancer
143	Desanvicente-Celis, Z., A. Gomez-Lopez and J. M. Anaya	2012	Similar biotherapeutic products: overview and reflections
144	Descatha, A., C. Dagrenat, P. Cassan, D. Jost, T. Loeb and M. Baer	2015	Cardiac arrest in the workplace and its outcome: a systematic review and meta-analysis
145	Di Girolamo, G., P. Czerniuk, R. Bertuola and G. A. Keller	2010	Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian subjects: a randomized, double-blind, crossover study
146	Di Girolamo, G., P. Czerniuk, R. Bertuola and G. A. Keller	2010	Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian subjects: a randomized, double-blind, crossover study
147	Di Girolamo, G., M. A. Kauffman, E. González, M. Papouchado, A. Ramirez, G. Keller, C. Carbonetto, S. Dabsys, A. Vidal, A. Sterin-Prync and R. A. Diez	2008	Bioequivalence of two subcutaneous pharmaceutical products of interferon beta-1a in healthy subjects: a randomized, double-blind, crossover study
148	Dias, C. R. and N. S. Romano-Lieber	2006	[Generic drug policy implementation in Brazil]
149	Diaz, J. A., E. Silva, M. J. Arias and M. Garzón	2011	Comparative in vitro study of the antimicrobial activities of different commercial formulations of amoxicillin
150	Díaz, L. P., S. Millán, N. Chaban, A. D. Campo and E. Spitzer	2021	Current state and comparison of the clinical development of bevacizumab, a biosimilar and its reference product
151	do Carmo, A. C., S. S. Piras, N. F. Rocha and T. Gratieri	2017	Main Reasons for Registration Application Refusal of Generic and Similar Medicines in Brazil (ANVISA)
152	Dos Reis Serra, C. H., E. E. Mori Koono, E. K. Kano, S. G. Schramm, Y. P. Armando and V. Porta	2008	Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy subjects: a randomized, double-blind, crossover study
153	Drageset, J., R. K. Sandvik, L. S. P. Eide, G. Austrheim, M. Fox and E. G. Beisland	2021	Quality of life among cancer inpatients 80 years and older: a systematic review
154	Drelichman, G., G. Castañeda-Hernández, M. Cem Ar, M. Dragosky, R. Garcia, H. Lee, S. Moiseev, M. Naderi, H. Rosenbaum, I. Žnidar, A. F. Zuluaga, S. Freisens and P. K. Mistry	2020	The road to biosimilars in rare diseases - ongoing lessons from Gaucher disease
155	Elliott, R.	2000	US files WTO complaints against Brazil over requirement for "local work"
156	Emery, P., J. Vencovský, A. Sylwestrzak, P. Leszczynski, W. Porawska, A. Baranaukaite, V. Tseluyko, V. M. Zhdan, B. Stasiuk, R. Milasiene, A. A. Barrera Rodriguez, S. Y. Cheong and J. Ghil	2017	52-week results of the phase 3 randomized study comparing SB4 with reference product in patients with rheumatoid arthritis
157	Emery, P., J. Vencovský, A. Sylwestrzak, P. Leszczyński, W. Porawska, A. Baranaukaite, V. Tseluyko, V. M. Zhdan, B. Stasiuk, R. Milasiene, A. A. Barrera Rodriguez, S. Y. Cheong and J. Ghil	2017	A phase III randomised, double-blind, parallel-group study comparing SB4 with reference product in patients with rheumatoid arthritis despite methotrexate therapy
158	Ensslin, L., A. Gonçalves, S. R. Ensslin, A. Dutra and A. A. Longaray	2022	Constructivist multi-criteria model to support the management of occupational health and safety
159	Epstein, S., B. Cryer, S. Ragi, J. R. Zanchetta, J. Walliser, J. Chow, M. A. Johnson and A. E. Leyes	2003	Disintegration/dissolution profiles of copies of Fosamax (alendronate)
160	Escobedo-Moratilla, A., A. P. Barba de la Rosa and J. T. Pérez-Urizar	2015	[Preclinical in vitro and in vivo models for the assessment of biological activity]
161	Escobedo-Moratilla, A., F. Kuri-Breña Romero de Terreros, J. Pérez-Urizar and A. P. Barba de la Rosa	2015	Analytical and Biological Characterization of a Noninnovator Insulin Glargine
162	Espinosa Morales, R., A. Díaz Borjón, L. A. Barile Fabris, J. A. Esquivel Valerio, G. Medrano Ramírez, C. A. Arce Salinas, E. R. Barreira Mercado, M. H. Cardiel Ríos, E. Díaz Jouanen, F. J. Flores Murrieta, A. Fraga Mouret, M. A. Garza Elizondo, M. Luján Estrada, F. J. Muñoz Barradas, J. O. Talavera Piña and O. L. Vera Lastra	2013	Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology
163	Espinosa-de la Garza, C. E., F. C. Perdomo-Abúndez, J. Padilla-Calderón, J. M. Uribe-Wiechers, N. O. Pérez, L. F. Flores-Ortiz and E. Medina-Rivero	2013	Analysis of recombinant monoclonal antibodies by capillary zone electrophoresis

	Journal
in Brazil; findings and implications	Expert review of pharmacoeconomics & outcomes research
n countries	The Journal of infectious diseases
on in Honduras	Journal of clinical microbiology
	Stat Med
e to the global burden of disease: results from the GBD 2010 study	PLoS one
arly Breast Cancer: ASCO Guideline Update	J Clin Oncol
	Immunotherapy
meta-analysis	Resuscitation
inian volunteers: a single-dose, randomized-sequence, open-label crossover	Clin Ther
inian volunteers: a single-dose, randomized-sequence, open-label crossover	Clinical therapeutics
n beta la	Arzneimittelforschung
	Cad Saude Publica
mercial antibiotic products of vancomycin	BMC Clin Pharmacol
rituximab and trastuzumab biosimilars	Future Oncol
Pharmaceutical Drug Products by the Brazilian Health Regulatory Agency	Biomed Res Int
healthy Brazilian volunteers: an open-label, randomized, single-dose, two-	Clinical therapeutics
view	Health and quality of life outcomes
sease	Am J Hematol
ing" of patents	Can HIV AIDS Policy Law Rev
erence etanercept in patients with active rheumatoid arthritis	Rheumatology (Oxford)
4 with etanercept reference product in patients with active rheumatoid	Ann Rheum Dis
onal accident risks in civil construction industry	PLoS One
	Curr Med Res Opin
tivity in biosimilarity studies]	Gac Med Mex
ngine and the Originator Drug Product	J Diabetes Sci Technol
ology, 2012	Reumatol Clin
horesis	Electrophoresis

Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	<b>Author</b>	<b>Year</b>	<b>Title</b>
164	Esquivel, A., R. González-Ramírez, J. Alberú, C. Gracida, M. Medeiros and G. Castañeda-Hernández	2010	Comparison of dissolution properties of 2 enteric-coated formulations containing
165	Etto, L. Y., V. M. Morelli, V. C. Silva, V. T. Hungria, R. M. Ciconelli, M. S. Almeida, J. S. Oliveira, J. C. Barros, B. G. Durie and G. W. Colleoni	2011	Autologous stem cell transplantation improves quality of life in economic
166	Ewen, M., H. J. Joosse, D. Beran and R. Laing	2019	Insulin prices, availability and affordability in 13 low-income and middle-
167	Fairman, K. A. and F. R. Curtiss	2007	The elephant in the pharmacy: patient choice is the big challenge that no o
168	Fávero-Retto, M. P., L. H. Guerreiro, C. M. Pessanha, L. C. Palmieri and Lmtr Lima	2017	Polymorphic distribution of proteins in solution by mass spectrometry: The
169	Fávero-Retto, M. P., L. C. Palmieri, T. A. Souza, F. C. Almeida and L. M. Lima	2013	Structural meta-analysis of regular human insulin in pharmaceutical formu
170	Feagan, B. G., M. Marabani, J. J. Wu, F. Faccin, C. Spronk and G. Castañeda-Hernández	2020	The Challenges of Switching Therapies in an Evolving Multiple Biosimila
171	Federal University of São, Paulo	2013	Therapeutic Equivalence Between Branded and Generic WARFArin Table
172	Fernandes, G. S., C. Sternberg, G. Lopes, R. Chammas, M. A. C. Gifoni, R. A. Gil and D. V. Araujo	2018	The use of biosimilar medicines in oncology - position statement of the Br
173	Fernandes, T. A. P., C. S. Magalhães, S. K. Oliveira, F. Sztajnbok, J. de Oliveira Sato, L. S. Darze, R. G. de Almeida, A. Consolaro, F. Bovis and N. Ruperto	2018	The Brazilian Portuguese version of the Juvenile Arthritis Multidimension
174	Fernandez, L., R. H. Bustos, C. Zapata, J. Garcia, E. Jauregui and G. M. Ashraf	2018	Immunogenicity in Protein and Peptide Based-Therapeutics: An Overview
175	Ferreira Neto, P. T. P., P. H. C. Nunes and M. A. Vargas	2019	[Interchangeability of biological products in the Brazilian Unified Nationa
176	Ferro, H. H., M. Juni, R. Bello, A. Vidal, R. A. Diez and S. Pavlovsky	2009	Utilization study of filgrastim (Neutromax) during autologous haematopo
177	Filho, E. P., N. R. da Costa Faria, A. M. Fialho, R. S. de Assis, M. M. S. Almeida, M. Rocha, M. Galvão, F. B. Dos Santos, M. L. Barreto and J. P. G. Leite	2007	Adenoviruses associated with acute gastroenteritis in hospitalized and com
178	Flandre, P., P. Pugliese, C. Allavena, C. Isnard Bagnis, L. Cuzin and Aids study Group Dat <sup>†</sup>	2016	Does first-line antiretroviral regimen impact risk for chronic kidney diseas
179	Fleischmann, R., V. Jairath, E. Mysler, D. Nicholls and P. Declerck	2020	Nonmedical Switching From Originators to Biosimilars: Does the Nocebo
180	Fonseca, E. M.	2015	Relevance of variation in use of terminology to define generic pharmaceut
181	Ford, N., D. Wilson, G. Costa Chaves, M. Lotrowska and K. Kijitwathakul	2007	Sustaining access to antiretroviral therapy in the less-developed world: les
182	Fraga, A. P., N. Ikuta, A. S. Fonseca, F. R. Spilki, E. Balestrin, C. D. Rodrigues, C. W. Canal and V. R. Lunge	2016	A Real-Time Reverse-Transcription Polymerase Chain Reaction for Differ
183	Fransen, A. F., J. van de Ven, F. R. Banga, B. W. J. Mol and S. G. Oei	2020	Multi-professional simulation-based team training in obstetric emergencies
184	Frazer, M. B., J. Bubalo, H. Patel, J. Siderov, M. Cubilla, M. De Lemos, H. Dhillon, J. Harchowal, N. Kuchonthara, A. Livinalli, R. Macedo, W. Mwangi, H. Nomura, S. O'Connor, M. Patterson, M. Seadi Torriani, B. Yim, A. Chan and E. Foreman	2020	International Society of Oncology Pharmacy Practitioners global position
185	Freitas, C. G., M. Walsh and N. Atallah Á	2017	Design and rationale for the WARFA trial: a randomized controlled cross-o
186	Freitas, C. G., M. Walsh and N. Atallah Á	2017	Design and rationale for the WARFA trial: a randomized controlled cross-o
187	Fuerte, V., M. Maldonado and G. D. Rees	1999	The multicomponent automated dissolution system: an alternative in the d
188	Galan-Herrera, J. F., J. L. Poo, O. Rosales-Sanchez, E. Fuentes-Fuentes, L. Cariño, V. Burke-Fraga, S. Namur and M. G. Parra	2009	Bioavailability of two oral formulations of a single dose of levofloxacin 50
189	Galindo, J., P. Amariles, H. F. Mueses-Marín, J. A. Hincapié, S. González-Avendaño and X. Galindo-Orrego	2016	Effectiveness and safety of generic version of abacavir/lamivudine and efa
190	Gallardo, W., M. I. de Las Casas and M. Mercado	2015	A cautionary note on generic depot octreotide
191	Ganguli, G.	2003	Consumers devise drug cost-cutting measures: medical and legal issues to
192	Garay, S. M., R. Cuttica, M. M. Katsicas, G. Espada, C. De Cunto, M. Fabi, J. Gomez Sosa, R. Russo, M. de Los Angeles Britos, A. Consolaro, F. Bovis and N. Ruperto	2018	The Argentinian Spanish version of the Juvenile Arthritis Multidimensiona

	Journal
maintaining mycophenolate sodium: Myfortic vs Femulan	Transplant Proc
ethically challenged, Brazilian multiple myeloma patients	Clinics (Sao Paulo, Brazil)
low-income countries	BMJ Glob Health
the article talks about in affordability of prescription drugs	J Manag Care Pharm
the analysis of insulin analogues	Biologicals
regulations	Eur J Pharm Biopharm
Therapeutic Landscape: A Narrative Review of Current Evidence	Adv Ther
clinical trials in Brazil	<a href="https://clinicaltrials.gov">clinicaltrials.gov</a>
Brazilian Society of Clinical Oncology (SBOC)	Braz J Med Biol Res
Journal Assessment Report (JAMAR)	Rheumatol Int
	Curr Protein Pept Sci
Public Health System (SUS): the main regulatory challenges]	Cad Saude Publica
Allogeneic precursor transplantation for myeloma and lymphoma patients	Transfus Apher Sci
community children up to 5 years old in Rio de Janeiro and Salvador, Brazil	Journal of medical microbiology
What is the risk group?	AIDS (London, England)
Effect Explain Treatment Failures and Adverse Events in Rheumatology and	Rheumatol Ther
Biological products	Rev Panam Salud Publica
Experiences from Brazil and Thailand	Aids
Characterization of Massachusetts Vaccine and Brazilian Field Genotypes of Avian	Avian diseases
Interventions for improving patient outcomes and trainees' performance	The Cochrane database of systematic reviews
Review on the use of biosimilars in cancer treatment and supportive care	J Oncol Pharm Pract
Randomized controlled trial testing the therapeutic equivalence of branded and generic warfarin	BMC Cardiovasc Disord
Randomized controlled trial testing the therapeutic equivalence of branded and generic warfarin	BMC cardiovascular disorders
Development and pharmaceutical analysis of generic polydrugs	J Pharm Biomed Anal
100 mg: an open-label, randomized, two-period crossover comparison in	Clinical therapeutics
efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-	BMC Infect Dis
	Pituitary
should we consider	Health Care Manag (Frederick)
Journal Assessment Report (JAMAR)	Rheumatol Int

Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	<b>Author</b>	<b>Year</b>	<b>Title</b>
193	García-Hidalgo, L., S. Méndez-Flores, S. Carrillo-Vázquez, L. Estrada-Aguilar, M. D. R. García-Salazar, M. Gómez-Flores, A. López-Tello, Y. Charli-Joseph, C. Maldonado-García and L. Serrano-Jaén	2020	Biosimilar medicines for psoriasis. Positioning of the Mexican Academy of
194	García-Nares, H., M. I. Leyva-Carmona, N. Pérez-Xochipa and E. Chiquete	2015	Hypersensitivity reaction to a biosimilar insulin glargine
195	Gauthier, G., R. Levin, F. Vekeman, J. M. Reyes, E. Chiarello and D. Ponce de Leon	2021	Treatment patterns and sequencing in patients with rheumatic diseases: a r
196	Genovese, M. C., J. Glover, M. Greenwald, W. Porawska, E. C. El Khouri, E. Dokoupilova, J. I. Vargas, M. Stanislavchuk, H. Kellner, E. Baranova, N. Matsunaga and R. Alten	2019	FKB327, an adalimumab biosimilar, versus the reference product: results o
197	Gentile, A., A. Bardach, A. Ciapponi, S. Garcia-Marti, P. Aruj, D. Glujovsky, J. I. Calcagno, A. Mazzoni and R. E. Colindres	2012	Epidemiology of community-acquired pneumonia in children of Latin Am
198	Ghabri, S., L. Lam, F. Bocquet and H. M. Spath	2020	Systematic Literature Review of Economic Evaluations of Biological Trea Previously Treated with Disease-Modifying Anti-rheumatic Drugs
199	Gheorghe, A., U. Griffiths, A. Murphy, H. Legido-Quigley, P. Lamptey and P. Perel	2018	The economic burden of cardiovascular disease and hypertension in low- a
200	Gifoni, M. A. C., G. S. Fernandes and R. Chammas	2018	Biosimilar Drugs: What Would Be a Reasonable Extrapolation?
201	Giraud, J. S., M. Doisne, A. Chan Hew Wai, C. Majerholc, E. Fourn, K. Sejean, J. Trichereau, B. Bonan and D. Zucman	2020	De-simplifying single-tablet antiretroviral treatments for cost savings in Fr
202	Gire, C., N. Resseguier, V. Brévaut-Malaty, S. Marret, G. Cambonie, I. Souksi-Medioni, J. B. Müller, P. Garcia, J. Berbis, B. Tosello, P. Auquier and G. PQoL study Group	2019	Quality of life of extremely preterm school-age children without major har
203	Glauser, B. F., B. C. Vairo, C. P. Oliveira, L. P. Cinelli, M. S. Pereira and P. A. Mourão	2011	Generic versions of enoxaparin available for clinical use in Brazil are simi
204	Glauser, B. F., B. C. Vairo, S. N. Oliveira, L. P. Cinelli, M. S. Pereira and P. A. Mourão	2012	Structure and haemostatic effects of generic versions of enoxaparin availab
205	Godman, B., J. Fadare, H. Y. Kwon, C. Z. Dias, A. Kurdi, I. P. Dias Godói, D. Kibuule, I. Hoxha, S. Opanga, Z. Saleem, T. Bochenek, V. Marković-Peković, I. Mardare, A. C. Kalungia, S. Campbell, E. Allocati, A. Pisana, A. P. Martin and J. C. Meyer	2021	Evidence-based public policy making for medicines across countries: findi
206	Godman, B., M. Haque, T. Leong, E. Allocati, S. Kumar, S. Islam, J. Charan, F. Akter, A. Kurdi, C. Vassalo, M. A. Bakar, S. A. Rahim, N. Sultana, F. Deeba, M. A. H. Khan, Abmm Alam, I. Jahan, Z. M. Kamal, H. Hasin, E. Murshid Munzur, S. Nahar, M. Haque, S. Dutta, J. P. Abhayanand, R. J. Kaur, G. M. Rwegerera, R.erm do Nascimento, I. P. Dias Godói, M. Irfan, A. A. Amu, P. Matowa, J. Acolatse, R. Incoom, I. A. Sefah, J. Acharya, S. Opanga, L. W. Njeri, D. Kimonge, H. Y. Kwon, S. Bae, K. K. P. Khuan, A. R. Abubakar, I. H. Sani, T. A. Khan, S. Hussain, Z. Saleem, O. O. Malande, T. Piloya-Were, R. Gambogi, C. Hernandez Ortiz, L. Alutuli, A. C. Kalungia, I. Hoxha, V. Marković-Peković, B. Tubic, G. Petrova, K. Tachkov, O. Laius, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, J. Gulbinović, M. Wladysiuk, J. Rutkowski, I. Mardare, J. Fürst, S. McTaggart, S. MacBride-Stewart, C. Pontes, C. Zara, E. T. Tagoe, R. Banzi, J. Wale and M. Jakovljevic	2021	The Current Situation Regarding Long-Acting Insulin Analogues Including Countries; Findings and Implications for the Future
207	Gomes, F. R., A. C. Maluenda, J. O. Tápias, F. L. Oliveira, L. C. Sá-Rocha, E. Carvalho and P. L. Ho	2012	Expression of recombinant human mutant granulocyte colony stimulating
208	Gomes Freitas, C., M. Walsh, E. L. Coutinho, A. A. Vincenzo de Paola and N. Atallah Á	2021	Examining therapeutic equivalence between branded and generic warfarin
209	Gomes Freitas, C., M. Walsh, E. L. Coutinho, A. A. Vincenzo de Paola and N. Atallah Á	2021	Examining therapeutic equivalence between branded and generic warfarin
210	Gomes, M., E. Ramacciotti, A. C. Henriques, G. R. Araujo, L. A. Szultan, F. Miranda, Jr. and I. Thethi	2011	Generic versus branded enoxaparin in the prevention of venous thromboem trial
211	Gomes, M., E. Ramacciotti, A. C. Henriques, G. R. Araujo, L. A. Szultan, F. Miranda and I. Thethi	2011	Generic versus branded enoxaparin in the prevention of venous thromboem trial
212	Gomes, M., E. Ramacciotti, D. Hoppensteadt, J. M. Walenga, B. Lewis, I. Thethi and J. Fareed	2011	An open label, non-randomized, prospective clinical trial evaluating the im volunteers

	Journal
f Dermatology	Gac Med Mex
	J Diabetes
retrospective claims data analysis	Curr Med Res Opin
of a randomized, Phase III, double-blind study, and its open-label extension	Arthritis Res Ther
erica and the Caribbean: a systematic review and meta-analysis	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
atment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis	Pharmacoeconomics
and middle-income countries: a systematic review	BMC public health
	J Glob Oncol
erance: From the patient perspectives to a 6-month follow-up on generics	PloS one
ndicap: a cross-sectional observational study	Archives of disease in childhood
lar to the original drug	J Thromb Haemost
ole for clinical use in Brazil: similarity to the original drug	Thromb Haemost
ings and implications for the future	J Comp Eff Res
g Biosimilars Among African, Asian, European, and South American	Front Public Health
factor (Nartograstim) in Escherichia coli	World J Microbiol Biotechnol
in Brazil: The WARFA crossover randomized controlled trial	PLoS One
in Brazil: The WARFA crossover randomized controlled trial	PloS one
mbolism following major abdominal surgery: report of an exploratory clinical	Clin Appl Thromb Hemost
mbolism following major abdominal surgery: report of an exploratory clinical	Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
mmunogenicity of branded enoxaparin versus biosimilars in healthy	Clin Appl Thromb Hemost



Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	<b>Author</b>	<b>Year</b>	<b>Title</b>
213	Gomez, C. D., A. Morel, I. Sedano and H. J. Aubin	2021	The efficacy of primavera, a prevention programme on alcohol and tobacco cluster study
214	Gómez-De León, A., E. Bugarin-Estrada, P. R. Colunga-Pedraza, J. E. Colunga-Pedraza, R. Salazar-Riojas, M. Valdés-Galván, Y. K. López-García, M. López-Garza, C. H. Gutiérrez-Aguirre, O. G. Cantú-Rodríguez, C. Mancías-Guerra, O. González-Llano and D. Gómez-Almaguer	2019	Efficacy of three filgrastim-intended copies for hematopoietic stem cell mo
215	Gomez-de-León, A., D. Gómez-Almaguer, G. J. Ruiz-Delgado and G. J. Ruiz-Arguelles	2017	Insights into the management of chronic myeloid leukemia in resource-poo
216	González, F. and F. González	2020	[Cost savings after switching from innovative tacrolimus to a generic versi
217	Gonzalez, J. M., C. A. Rodriguez, A. F. Zuluaga, M. Agudelo and O. Vesga	2015	Demonstration of Therapeutic Equivalence of Fluconazole Generic Produ
218	González-Consuegra, Renata Virginia and José Verdú	2011	Quality of life in people with venous leg ulcers: An integrative review
219	Gonzalez-Martinez, F., S. Orihuela, N. Orihuela, L. Manzo, N. Nuñez and M. Nin	2014	Descriptive retrospective comparative study between two brands of mycop
220	González-Ramírez, R., J. González-Bañuelos, L. Villa Mde, B. Jiménez, P. García-Roca, L. Cruz-Antonio, G. Castañeda-Hernández and M. Medeiros	2014	Bioavailability of a generic of the immunosuppressive agent mycophenola
221	Gorris, M. E., C. D. Shelley, S. Y. Del Valle and C. A. Manore	2021	A time-varying vulnerability index for COVID-19 in New Mexico, USA u
222	Gorzoni, M. L., R. M. Fabbri and S. L. Pires	2008	[Beer-Fick criteria and generic drugs in Brazil]
223	Gouveia, E. L., J. N. Reis, B. Flannery, S. M. Cordeiro, J. B. Lima, R. M. Pinheiro, K. Salgado, A. V. Mascarenhas, M. G. Carvalho, B. W. Beall, M. G. Reis and A. I. Ko	2011	Clinical outcome of pneumococcal meningitis during the emergence of per
224	Guilhoto, L. M., A. C. Mosini, M. A. Susemihl and L. F. Pinto	2021	COVID-19 and epilepsy: How are people with epilepsy in Brazil?
225	Gutierrez-Suarez, R., R. Burgos-Vargas, G. Burgos-Martinez, A. Consolaro, F. Bovis and N. Ruperto	2018	The Mexican Spanish version of the Juvenile Arthritis Multidimensional A
226	Halim, L. A., M. Márquez, R. F. Maas-Bakker, G. Castañeda-Hernández, W. Jiskoot and H. Schellekens	2018	Quality Comparison of Biosimilar and Copy Filgrastim Products with the
227	Halpern, M., B. Lachmansingh, T. Minior, L. M. Hasbrouck, N. Persaud and A. Foo	2010	Implementation of a standardized HIV patient monitoring system in Guyan
228	Hassett, B., M. Scheinberg, G. Castañeda-Hernández, M. Li, U. R. K. Rao, E. Singh, E. Mahgoub, J. Coindreau, J. O'Brien, S. M. Vicik and B. Fitzpatrick	2018	Variability of intended copies for etanercept (Enbrel®): Data on multiple b
229	Hauptman, P. J., Z. D. Goff, A. Vidic, J. T. Chibnall and B. E. Bleske	2017	Variability in Retail Pricing of Generic Drugs for Heart Failure
230	Hegg, R., A. Mattar, J. N. Matos-Neto, J. L. Pedrini, S. B. Aleixo, R. O. Rocha, R. P. Cramer-Junior and S. van-Eyll-Rocha	2016	A phase III, randomized, non-inferiority study comparing the efficacy and induced neutropenia in breast cancer patients
231	Heinemann, L., H. Khatami, R. McKinnon and P. Home	2015	An Overview of Current Regulatory Requirements for Approval of Biosim
232	Helfer, A. P., A. L. Camargo, N. U. Tavares, P. Kanavos and A. D. Bertoldi	2012	[Affordability and availability of drugs for treatment of chronic diseases in
233	Helou, N., A. Dwyer, M. Shaha and A. Zanchi	2016	Multidisciplinary management of diabetic kidney disease: a systematic rev
234	Hernández-Vásquez, A., C. A. Alarcon-Ruiz, G. Bendezu-Quispe, D. Comandé and D. Rosselli	2018	A bibliometric analysis of the global research on biosimilars
235	Herrera-Goepfert, R., M. Lizano, S. Akiba, A. Carrillo-García and M. Becker-D'Acosta	2009	Human papilloma virus and esophageal carcinoma in a Latin-American re
236	Hill, A., D. Gotham, G. Cooke, S. Bhagani, I. Andrieux-Meyer, J. Cohn and J. Fortunak	2015	Analysis of minimum target prices for production of entecavir to treat hep
237	Hochhaus, G., C. Davis-Cutting, M. Oliver, S. L. Lee and S. Lyapustina	2015	Current Scientific and Regulatory Approaches for Development of Orally Florida Orlando Inhalation Conference
238	Holmes, C. B., W. Coggin, D. Jamieson, H. Mihm, R. Granich, P. Savio, M. Hope, C. Ryan, M. Moloney-Kitts, E. P. Goosby and M. Dybul	2010	Use of generic antiretroviral agents and cost savings in PEPFAR treatment
239	Holmes, C. B., W. Coggin, D. Jamieson, H. Mihm, R. Granich, P. Savio, M. Hope, C. Ryan, M. Moloney-Kitts, E. P. Goosby and M. Dybul	2010	Use of generic antiretroviral agents and cost savings in PEPFAR treatment
240	Homero de Souza Filho, J., F. N. Bonifácio, D. C. Bedor, V. L. Ramos, C. E. de Sousa, L. L. Sardón, T. M. Gonçalves, R. C. Moreira, L. B. Leal and D. P. de Santana	2010	Relative bioavailability of two formulations of venlafaxine extended-release randomized-sequence, open-label, two-period crossover study in the fastin
241	Hörl, W. H.	2013	Differentiating factors between erythropoiesis-stimulating agents: an upda
242	Horta-Baas, G.	2022	Patient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration

	Journal
o use among 10–12-year-old schoolchildren: A randomized controlled	Int. J. Environ. Res. Public Health
obilization in healthy adult and pediatric donors in Mexico	J Clin Apher
or settings: a Mexican perspective	Expert Rev Hematol
ion of the drug in transplant recipients]	Rev Med Chil
cts in the Neutropenic Mouse Model of Disseminated Candidiasis	PLoS One
	Journal of Advanced Nursing
phenolate mofetil used in Uruguay: innovator versus generic (Suprimun)	Transplant Proc
te mofetil in pediatric patients	Pediatr Transplant
sing generalized propensity scores	Health policy OPEN
	Rev Assoc Med Bras (1992)
ncillin-resistant Streptococcus pneumoniae: an observational study	BMC infectious diseases
	Epilepsy & behavior : E&B
assessment Report (JAMAR)	Rheumatol Int
Innovator Product	Pharm Res
na	Revista panamericana de salud publica = Pan American journal of public health
atches of seven products	MAbs
	JAMA Intern Med
safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-	Clinics (Sao Paulo)
ilar Insulins	Diabetes Technol Ther
the public health care system]	Rev Panam Salud Publica
iew and meta-analysis	JB database of systematic reviews and implementation reports
	J Pharm Policy Pract
gion	World journal of gastroenterology : WJG
atitis B in high- and low-income countries	Journal of virus eradication
Inhaled and Nasal Drug Products: Overview of the IPAC-RS/University of	Aaps j
programs	Jama
programs	JAMA
se 75-mg capsules in healthy brazilian male volunteers: A single-dose, g and fed states	Clinical therapeutics
te to selection for anaemia of chronic kidney disease	Drugs
for Evaluating Biosimilar Uptake?	Patient Relat Outcome Meas

Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	Author	Year	Title
243	Hurtado y de la Peña, M., Y. Vargas Alvarado, A. M. Domínguez-Ramírez and A. R. Cortés Arroyo	2003	Comparison of dissolution profiles for albendazole tablets using USP apparatus
244	Ibarra, M., M. Vázquez and P. Fagiolino	2017	Sex Effect on Average Bioequivalence
245	Ikwaki, N., M. Iwasaki, G. Kurosawa, K. S. Rao, J. Lakey-Beitia, S. Preethy and S. J. Abraham	2021	β-glucans: wide-spectrum immune-balancing food-supplement-based enter
246	Iñesta, A. and L. A. Oteo	2011	[The pharmaceutical industry and the sustainability of healthcare systems]
247	Instituto de Efectividad Clínica y, Sanitaria	2020	Remdesivir in COVID-19 patients
248	Instituto de Efectividad Clínica y, Sanitaria	2020	Prone positioning in COVID-19 infection
249	Izidoro, J. B., T. Piazza, E. I. G. Andrade and J. Alvares-Teodoro	2019	[Budget impact of the incorporation of second-line drug treatment for diabetes from the perspective of the Minas Gerais State Health Department, Brazil]
250	Jacob, R. S., L. V. Santos, A. F. de Souza and L. C. Lange	2016	A toxicity assessment of 30 pharmaceuticals using <i>Aliivibrio fischeri</i> : a co
251	Jacomet, C., C. Allavena, F. Peyrol, B. Pereira, L. M. Joubert, H. Bagheri, L. Cotte, R. Garaffo, L. Gerbaud and P. Dellamonica	2015	Perception of antiretroviral generic medicines: one-day survey of HIV-inf
252	Jain, D. and J. J. Darrow	2013	An exploration of compulsory licensing as an effective policy tool for anti
253	Jakovljevic, M., Y. Liu, A. Cerda, M. Simonyan, T. Correia, R. M. Mariita, A. S. Kumara, L. Garcia, K. Krstic, R. Osobohien, T. K. Toan, C. Adhikari, N. T. K. Chuc, R. B. Khatri, V. K. Chattu, L. Wang, T. Wijerane, E. Kouassi, H. N. Khan and M. Varjacic	2021	The Global South political economy of health financing and spending land
254	Jakovljevic, M., W. Wu, J. Merrick, A. Cerda, M. Varjacic and T. Sugahara	2021	Asian innovation in pharmaceutical and medical device industry - beyond
255	Jannuzzi, A. H. L. and A. G. Vasconcellos	2017	[How much does the backlog on drug patents cost for health in Brazil?]
256	Jelkmann, W.	2009	Erythropoiesis stimulating agents and techniques: a challenge for doping a
257	Jiménez-Romero, C., J. Simithy, A. Severdia, D. Álvarez, M. Grosso, N. Spivey, A. Arias, P. N. Solís, J. Li and I. J. Hidalgo	2020	Near infrared (NIR)-spectroscopy and in-vitro dissolution absorption syste
258	Jimenez-Toro, I., C. A. Rodriguez, A. F. Zuluaga, J. D. Otalvaro and O. Vesga	2020	A new pharmacodynamic approach to study antibiotic combinations again
259	Johnson, M. B. and J. D. Clapp	2011	Impact of providing drinkers with "know your limit" information on drinki
260	Jones, S. G.	2002	HIV medication adherence: from Haitian DOT to generics in Brazil
261	Jozala, A. F., D. C. Gerales, L. L. Tundisi, V. A. Feitosa, C. A. Breyer, S. L. Cardoso, P. G. Mazzola, L. Oliveira-Nascimento, C. O. Rangel-Yagui, P. O. Magalhães, M. A. Oliveira and A. Pessoa, Jr.	2016	Biopharmaceuticals from microorganisms: from production to purification
262	Jurczak, W., I. Moreira, G. B. Kanakasetty, E. Munhoz, M. A. Echeveste, P. Giri, N. Castro, J. Pereira, L. Akria, S. Alexeev, E. Osmanov, P. Zhu, S. Alexandrova, A. Zubel, O. Harlin and J. Amersdorffer	2017	Rituximab biosimilar and reference rituximab in patients with previously u a confirmatory phase 3, double-blind, randomised, controlled study
263	Kameda, H., E. Uechi, T. Atsumi, C. Abud-Mendoza, K. Kamei, T. Matsumoto, D. Ponce de Leon, M. I. Rehman, M. Zhang and S. C. Radominski	2020	A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) a rheumatoid arthritis: A subgroup analysis
264	Keller, G. A., P. Czerniuk, R. Bertuola, J. G. Spatz, A. R. Assefi and G. Di Girolamo	2011	Comparative bioavailability of 2 tablet formulations of levodopa/benserazid label crossover study
265	Kolberg, H. C., M. Colleoni, G. S. Demetriou, P. Santi, H. Tesch, Y. Fujiwara, Z. Tomasevic and V. Hanes	2020	Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HI Controlled LILAC Study
266	Kolberg, H. C., M. Colleoni, P. Santi, G. S. Demetriou, M. A. Segui-Palmer, Y. Fujiwara, S. A. Hurvitz and V. Hanes	2019	Totality of Scientific Evidence in the Development of ABP 980, a Biosimi
267	Kollross, B., M. Cunha-Filho, G. M. Gelfuso and T. Gratieri	2019	Regulatory Requirements and Innovation: A Comparison of the Dermatolo
268	Kotze, P. G. and S. Danese	2019	Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind
269	Kowalski, S. C., J. A. Benavides, P. A. Beltrán, C. Galarza-Maldonado, C. V. Caballero-Uribe, E. R. Soriano, C. Pineda, V. F. Azevedo, G. Avila-Pedretti, A. M. Babini, A. Cachafeiro-Vilar, M. Cifuentes-Alvarado, S. B. Cohen, P. E. Díaz, J. F. Diaz-Coto, C. Encalada, B. Garro, I. A. G. Sario, M. Guibert-Toledano, V. J. K. Rodriguez, M. E. L. Lopez, A. P. Ortega, A. S. Russell, P. Santos-Moreno, I. S. Terán, A. Vargas, G. Vásquez, R. M. Xavier, D. X. X. Firedman, E. Mysler and J. Kay	2019	Correction to: PANLAR consensus statement on biosimilars

	Journal
tratus 2 and 4	Drug Dev Ind Pharm
	Clin Ther
ric (β-WIFE) vaccine adjuvant approach to COVID-19	Hum Vaccin Immunother
n developed countries and in Latin America]	Cien Saude Colet
etic macular edema in the Brazilian Unified National Health System from	Cad Saude Publica
mparison of the acute effects of different formulations	Environ Technol
ected patients and their physicians in France	PloS one
retroviral drugs in India	Health Matrix Clevel
scape - history and presence	J Med Econ
tomorrow	J Med Econ
	Cad Saude Publica
analysts	Curr Med Chem
m 2 (IDAS2) can help detect changes in the quality of generic drugs	Drug Dev Ind Pharm
st enterococci in vivo: Application to ampicillin plus ceftriaxone	PLoS One
ing and driving: a field experiment	Journal of studies on alcohol and drugs
	Fla Nurse
	Braz J Microbiol
untreated advanced follicular lymphoma (ASSIST-FL): primary results from	Lancet Haematol
nd reference infliximab in patients with moderate to severe active	Int J Rheum Dis
de in healthy, fasting volunteers: a single-dose, randomized-sequence, open-	Clin Ther
ER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-	Drug Saf
lar to Trastuzumab	Target Oncol
gic Antifungal Drug Product Markets in Brazil and United States	Ther Innov Regul Sci
the Gap?	Curr Med Chem
	Clin Rheumatol

Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	Author	Year	Title
270	Kowalski, S. C., J. A. Benavides, P. A. B. Roa, C. Galarza-Maldonado, C. V. Caballero-Uribe, E. R. Soriano, C. Pineda, V. F. Azevedo, G. Avila-Pedretti, A. M. Babini, A. Cachafeiro-Vilar, M. Cifuentes-Alvarado, S. B. Cohen, P. E. Diaz, L. D. Soto, C. Encalada, B. Garro, I. A. G. Sariego, M. Guibert-Toledano, V. J. K. Rodriguez, M. E. L. Lopez, A. P. Ortega, A. S. Russell, P. Santos-Moreno, I. S. Terán, A. Vargas, G. Vásquez, R. M. Xavier, D. X. X. Firedman, E. Mysler and J. Kay	2019	PANLAR consensus statement on biosimilars
271	Kowalyszyn, R. D., L. E. Fein, M. E. Richardet, M. S. Varela, E. Ortiz, C. Micheri, J. J. Zarba, S. Kahl, E. Klimovsky, A. A. Federico, J. H. Cassini, G. Cortese and N. Lago	2022	Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Blinded, Noninferiority Study
272	Kurizky, P. S., L. O. Galvão and G. A. Martins	2019	Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis
273	Kwak, L. W., J. M. Sancho, S. G. Cho, H. Nakazawa, J. Suzumiya, G. Tumyan, J. S. Kim, T. Menne, J. Mariz, N. Ilyin, W. Jurczak, A. Lopez Martinez, O. Samoilo, E. Zhavrid, E. Yañez Ruiz, M. Trneny, L. Popplewell, M. Ogura, W. S. Kim, S. J. Lee, S. H. Kim, K. Y. Ahn and C. Buske	2022	Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor Burden Patients: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
274	Kwan, P. and A. Palmini	2017	Association between switching antiepileptic drug products and healthcare utilization
275	Lainesse, A., Y. Ozalp, H. Wong and R. S. Alpan	2004	Bioequivalence study of clopidogrel bisulfate film-coated tablets
276	Lammers, P., C. Criscitiello, G. Curigliano and I. Jacobs	2014	Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential for Biosimilars in Emerging Markets
277	Lange, J. M. and J. Ananworanich	2014	The discovery and development of antiretroviral agents
278	Lavalle-González, F. J. and H. Khatami	2014	The biosimilar insulin landscape: current developments
279	Leal, A. S., M. A. Menezes, R. R. Rodrigues, O. Andonie, P. Vermaercke and L. Sneyers	2008	A comparative neutron activation analysis study of common generic manipulations of a pharmaceutical product
280	Leclerc, J., M. Thibault, J. Midiani Gonella, C. Beaudoin and J. Sampalis	2020	Are Generic Drugs Used in Cardiology as Effective and Safe as their Branded Counterparts?
281	Lee, J. H., S. H. Eun, S. H. Kim, H. J. Ju, G. M. Kim and J. M. Bae	2020	Excimer laser/light treatment of alopecia areata: A systematic review and meta-analysis
282	Leone, M. A., E. Beghi, C. Righini, G. Apolone and P. Mosconi	2005	Epilepsy and quality of life in adults: a review of instruments
283	León-González, M., A. A. León-Peña, Villalobos M. F. Vallejo, A. K. Núñez-Cortés, A. Ruiz-Argüelles and G. J. Ruiz-Argüelles	2016	Mexican Biosimilar Filgrastim for Autologous Hematopoietic Stem Cell Transplantation
284	Leporowski, A., B. Godman, A. Kurdi, S. MacBride-Stewart, M. Ryan, S. Hurdling, R. C. Do Nascimento, M. Bennie and A. Morton	2018	Ongoing activities to optimize the quality and efficiency of lipid-lowering drugs
285	Li, R. K., E. Tokunaga, H. Adamchuk, V. Vladimirov, E. Yanez, K. S. Lee, I. Bondarenko, A. Vana, F. Hilton, T. Ishikawa, K. Tajima and O. Lipatov	2022	Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) in Patients with HER2-Positive Breast Cancer: Updated Results of a Randomized, Double-Blind Study
286	Lifshitz, A., J. Sallovitz, F. Imperiale, A. Pis, J. Jauregui Lorda and C. Lanusse	2004	Pharmacokinetic evaluation of four ivermectin generic formulations in calves
287	Lima, M. A., E. H. de Farias, A. Gray, N. Sadeghi, T. F. Gesteira, R. P. Cavalheiro, D. Hoppensteadt, J. Fareed, G. L. Sasaki and H. B. Nader	2012	Structural and pharmacological profile of generic enoxaparins used in Brazil
288	Lopes, R. A. and A. Neves Fde	2010	Meta-analysis for bioequivalence studies: interchangeability of generic drugs with the reference product: Enalapril Maleate
289	López, J. J., Y. Cortázar, Á Acosta, C. M. Vargas-Peláez and F. Rossi	2018	Drug utilization study of two generic antibiotics in a tertiary hospital in Bogotá
290	López-Morales, C. A., M. P. Miranda-Hernández, L. C. Juárez-Bayardo, N. D. Ramírez-Ibáñez, A. J. Romero-Díaz, N. Piña-Lara, V. R. Campos-García, N. O. Pérez, L. F. Flores-Ortiz and E. Medina-Rivero	2015	Physicochemical and biological characterization of a biosimilar trastuzumab
291	Lozada-Requena, I., C. Núñez and J. L. Aguilar	2015	[Melanoma immunotherapy: dendritic cell vaccines]
292	Luchese, M. D., M. Lopes Dos Santos, A. Garbuio, R. C. Targino, C. P. Mansueli, L. R. Tsuruta, W. Quintilio and A. M. Moro	2018	A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFR1 antibody
293	Machado-Alba, J. E., A. F. Ruiz and M. E. Machado-Duque	2014	Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs
294	Maddineni, J., J. M. Walenga, W. P. Jeske, D. A. Hoppensteadt, J. Fareed, R. Wahi and R. L. Bick	2006	Product individuality of commercially available low-molecular-weight heparins
295	Mahan, C. E. and J. Fanikos	2011	New antithrombotics: the impact on global health care
296	Maia, M. B., I. L. Martins, D. F. do Nascimento, A. N. Cunha, F. E. de Lima, F. A. Bezerra, M. O. Moraes and M. E. Moraes	2008	Validation of a reversed-phase high-performance liquid chromatography method for the determination of norfloxacin in plasma samples

	Journal
	Clin Rheumatol
Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-	JCO Glob Oncol
psoriasis and psoriatic arthritis: 1-year follow-up	An Bras Dermatol
High-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III	Clin Lymphoma Myeloma Leuk
Drug Utilization: A systematic review	Epilepsy Behav
	Arzneimittel-Forschung
Therapeutic Potential Impact of Biosimilars: A Physician Survey in the United States and	Pharmaceuticals (Basel)
	Antivir Ther
	Postgrad Med
Generic and reference medicines commercialized in Brazil	Appl Radiat Isot
Generic-name Counterparts? A Systematic Review and Meta-analysis	Drugs
Generic-name meta-analyses	Photodermatology, photoimmunology & photomedicine
	Epilepsy research
Cellular Mobilization and Transplantation	Rev Invest Clin
Generic drugs in the Scottish national health service: influence and implications	Expert Rev Pharmacoecon Outcomes Res
Generic (similar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer:	BioDrugs
Generic drugs	Vet Parasitol
Generic drugs in Brazil	Clin Appl Thromb Hemost
Generic drugs and similar containing Hydrochlorothiazide is possible but not with	Jornal brasileiro de nefrologia : 'orgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
Generic drugs in Bogotá	Biomedica
Generic drugs in Brazil	Biomed Res Int
	Rev Peru Med Exp Salud Publica
Generic drugs monoclonal antibody with biosimilar potential	Immunol Res
Generic drugs rheumatic drugs in patients with rheumatoid arthritis	Rev Panam Salud Publica
Generic drugs parins and their generic versions: therapeutic implications	Clin Appl Thromb Hemost
	Thromb Res
Generic drugs method with fluorescence detection for the bioequivalence study of	Ther Drug Monit

Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	<b>Author</b>	<b>Year</b>	<b>Title</b>
297	Malagon, C., A. C. Mosquera Pongutà, J. De Inocencio, A. Consolaro, F. Bovis and N. Ruperto	2018	The Colombian Spanish version of the Juvenile Arthritis Multidimensional
298	Mallol, J., V. Aguirre, A. Gallardo, E. Cortez, C. Sánchez, C. Riquelme, P. Córdova, M. Martínez and A. Galindo	2016	Effect of once-daily generic ciclesonide on exhaled nitric oxide in atopic c
299	Manzi, L., N. Sepe, W. Migliaccio, L. Lanzoni, L. Iozzino, F. D'Angelo, L. Colarusso, S. Montenegro, A. Palmese, T. D'Hooghe, A. Ulloa-Aguirre, Y. Koloda and M. Lispi	2022	Comparative Assessment of the Structural Features of Originator Recombi Biosimilar Preparations Approved in Non-European Regions
300	Marciano, S., L. Haddad, M. V. Reggiardo, M. Peralta, C. Vistarini, M. Marino, V. I. Descalzi, C. D'Amico, S. Figueroa Escuti, L. A. Gaite, R. Perez Ravier, C. Longo, S. M. Borzi, O. A. Galdame, F. Bessone, H. A. Fainboim, S. Frías, M. Cartier and A. C. Gadano	2018	Effectiveness and safety of original and generic sofosbuvir for the treatment
301	Martin, G. T., S. S. Yoon and K. E. Mott	1991	ZOOM: a generic personal computer-based teaching program for public he
302	Martínez, V. P. M., L. Tierrablanca-Sánchez, C. E. Espinosa-de la Garza, L. C. Juárez-Bayardo, N. Piña-Lara, G. G. Santoyo and N. O. Pérez	2020	Functional analysis of glycosylation in Etanercept: Effects over potency an
303	Martínez-Vázquez, M. A., M. C. Rodríguez-Leal and F. J. Bosques-Padilla	2010	[Considerations in evaluating the quality of life of patients with digestive,
304	May, S. B., P. F. Barroso, E. P. Nunes, H. S. Barcaui, M. M. Almeida, M. D. Costa, J. C. Faulhaber, G. Santoro-Lopes and M. Schechter	2007	Effectiveness of highly active antiretroviral therapy using non-brand name
305	Mayoral-Zavala, A., A. Esquivel-Aguilar, C. M. Del Real-Calzada, Y. Gutiérrez-Grobe, J. Ramos-García, J. L. Rocha-Ramírez, M. F. Rojas-Illanes, B. Rubio-Martínez, X. Sánchez-Chávez and J. K. Yamamoto-Furusho	2018	Update on biosimilars in inflammatory bowel disease: Position and recom
306	Mazzoleni, L. E., C. F. Francesconi and G. B. Sander	2011	Mass eradication of <i>Helicobacter pylori</i> : feasible and advisable?
307	Meager, A., C. Dolman, P. Dilger, C. Bird, G. Giovannoni, H. Schellekens, R. Thorpe and M. Wadhwa	2011	An assessment of biological potency and molecular characteristics of diffe
308	Medeiros, M., J. Lumini, N. Stern, G. Castañeda-Hernández and G. Filler	2018	Generic immunosuppressants
309	Medina, A. P., F. J. Olaya, M. P. Navas, A. M. Tilano and E. Muñoz	2012	[Bioequivalence study of montelukast 5 mg chewable tablets]
310	Megna, M., A. Villani, L. Potestio, E. Camela, G. Fabbrocini and S. S. Ocampo-Garza	2022	Adalimumab biosimilar in a pediatric patient: Clinical and in vivo reflectar
311	Meiners, C., L. Sagaon-Teyssier, L. Hasenclever and J. P. Moatti	2011	Modeling HIV/AIDS drug price determinants in Brazil: is generic competi
312	Melgaço, F. G., M. L. Rosa, E. F. Augusto, J. G. Haimuri, C. Jacintho, L. S. Santos, S. M. Cavalcanti and L. H. Oliveira	2011	Human papillomavirus genotypes distribution in cervical samples from wo
313	Méndez-Alburez, L. P. and A. Cerón	2016	[Not Available]
314	Méndez-Martínez, R., N. E. Rivera-Martínez, B. Crabtree-Ramírez, J. G. Sierra-Madero, Y. Caro-Vega, S. C. Galván, D. C. de León and A. García-Carranca	2014	Multiple human papillomavirus infections are highly prevalent in the anal men
315	Mendonça, J. M., D. P. Lyra, Jr., J. S. Rabelo, J. S. Siqueira, B. J. Balisa-Rocha, F. R. Gimenes and L. R. Bonjardim	2010	Analysis and detection of dental prescribing errors at primary health care u
316	Meurice, J. C., P. Ingrand, F. Portier, I. Arnulf, D. Rakotonanahari, E. Fournier, F. Philip-Joet, D. Veale and Cmts Antadir Antadir Working Group "Ppc	2007	A multicentre trial of education strategies at CPAP induction in the treatme
317	Mezones-Holguin, E., R. V. Gamboa-Cardenas, G. Sanchez-Felix, J. Chávez-Corrales, L. M. Helguero-Santin, L. M. Laban Seminario, P. A. Burela-Prado, M. M. Castro-Reyes and F. Fiestas	2019	Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Decision-Making From a Latin-American Country
318	Michalowski, M. B. and D. K. Cecconello	2021	Comment on: Unsatisfactory quality of <i>E. coli</i> asparaginase biogenerics in
319	Migliavacca Zucchetti, B., E. Nicolò and G. Curigliano	2019	Biosimilars for breast cancer
320	Miguel Haddad Kury, C., Kcds Santos, F. N. Carestiatto, G. Rapozo, C. G. Leandro, L. A. Fernandes, P. R. T. Silva, M. R. L. Passos, O. G. Cruz and S. M. B. Cavalcanti	2021	Human papillomavirus prevalence, genomic diversity and related risk facto Janeiro
321	Milán-Segovia, R. C., A. M. Domínguez-Ramírez, H. Jung-Cook, M. Magaña-Aquino, M. C. Romero-Méndez, S. E. Medellín-Garibay, M. Vigna-Pérez and S. Romano-Moreno	2010	Relative bioavailability of rifampicin in a three-drug fixed-dose combinati
322	Milán-Segovia, R. C., M. Vigna-Pérez, M. C. Romero-Méndez, S. E. Medellín-Garibay, J. M. Vargas-Morales, M. Magaña-Aquino and S. Romano-Moreno	2014	Relative bioavailability of isoniazid in a fixed-dose combination product in

	Journal
Assessment Report (JAMAR)	Rheumatol Int
children with persistent asthma	Allergol Immunopathol (Madr)
nant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa	Int J Mol Sci
nt of chronic hepatitis C: A real world study	J Med Virol
health and its application in schistosomiasis control	Bulletin of the World Health Organization
nd stability	Eur J Pharm Sci
liver and bile disorders in Mexico]	Revista de gastroenterología de México
drugs in Brazil	Braz J Med Biol Res
recommendations in Mexico	Rev Gastroenterol Mex (Engl Ed)
	Lancet
rent innovator and noninnovator interferon-beta products	J Interferon Cytokine Res
	Pediatr Nephrol
	Biomedica
nce confocal microscopy evaluation	Dermatol Ther
tion a myth?	PLoS One
women living with human immunodeficiency virus	Archives of gynecology and obstetrics
	Salud Publica Mex
canal of human immunodeficiency virus-positive men who have sex with	BMC infectious diseases
units in Brazil	Pharm World Sci
ent of severe sleep apnoea-hypopnoea syndrome	Sleep medicine
Patients Receiving Infliximab: A Systematic Review in the Context of	Front Pharmacol
India: Implications for clinical outcomes in acute lymphoblastic leukaemia	Pediatr Blood Cancer
	Expert Opin Biol Ther
ors in HIV-positive women from a countryside city in the state of Rio de	Human vaccines & immunotherapeutics
on formulation	Int J Tuberc Lung Dis
h healthy Mexican subjects	Int J Tuberc Lung Dis



Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	Author	Year	Title
323	Miranda-Hernández, M. P., C. A. López-Morales, F. C. Perdomo-Abúndez, R. D. Salazar-Flores, N. D. Ramírez-Ibanez, N. O. Pérez, A. Molina-Pérez, J. Revilla-Beltri, L. F. Flores-Ortiz and E. Medina-Rivero	2016	New Alternatives for Autoimmune Disease Treatments: Physicochemical a
324	Miranda-Hernández, M. P., C. A. López-Morales, F. C. Perdomo-Abúndez, R. D. Salazar-Flores, N. D. Ramírez-Ibanez, N. O. Pérez, A. Molina-Pérez, J. Revilla-Beltri, E. Medina-Rivero and L. F. Flores-Ortiz	2018	Response to: Comment on "New Alternatives for Autoimmune Disease Tre Etanercept"
325	Miranda-Hernández, M. P., C. A. López-Morales, N. Piña-Lara, F. C. Perdomo-Abúndez, N. O. Pérez, J. Revilla-Beltri, A. Molina-Pérez, L. Estrada-Marín, L. F. Flores-Ortiz, A. Ruiz-Argüelles and E. Medina-Rivero	2015	Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated f
326	Moizard, V., T. Lansaman, E. Mauruc Soubirac, M. Revol, B. Coulet, C. Hugeron, A. Gelis and I. Laffont	2021	Assessment of the upper limb of the tetraplegic patient
327	Molise, M. C., A. F. Maffey, P. Ramos and F. Rubinstein	2012	Original salbutamol versus similar salbutamol in children with asthma exa
328	Moots, R., V. Azevedo, J. L. Coindreau, T. Dörner, E. Mahgoub, E. Mysler, M. Scheinberg and L. Marshall	2017	Switching Between Reference Biologics and Biosimilars for the Treatment Conditions: Considerations for the Clinician
329	Moots, R. J., C. Curiale, D. Petersel, C. Rolland, H. Jones and E. Mysler	2018	Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimil Review
330	Mora, C. H., S. M. Garay, A. Consolaro, F. Bovis and N. Ruperto	2018	The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensiona
331	Morel Ayala, Z., R. Burgos-Vargas, A. Consolaro, F. Bovis and N. Ruperto	2018	The Paraguayan Spanish version of the Juvenile Arthritis Multidimensiona
332	Moreno-Montoya, J., A. M. Barragán, M. Martínez, A. Rodríguez and C. González Á	2018	Quality of life and perceived social support in people with HIV in Bogotá,
333	Morgiève, M., K. N'Diaye, A. H. Clair, A. Pelissolo and L. Mallet	2016	[Can the efficacy of behavioral and cognitive therapy for obsessive compu
334	Moss, B. P. and J. A. Cohen	2019	The emergence of follow-on disease-modifying therapies for multiple scler
335	Mouelhi, Y., E. Jouve, C. Castelli and S. Gentile	2020	How is the minimal clinically important difference established in health-re
336	Mourão, P. A., B. F. Glauser, B. C. Vairo and M. S. Pereira	2012	Propositional debate on biosimilar enoxaparin in Brazil
337	Mufarrije, E. F., L. A. Haile, M. Etcheverrigaray and D. I. Verthelyi	2019	Multiplexed Gene Expression as a Characterization of Bioactivity for Inter Response Modulating Impurities (IIRMI)
338	Muhsen, I. N., S. K. Hashmi, D. Niederwieser, N. Kroeger, S. Agrawal, M. C. Pasquini, Y. Atsuta, K. K. Ballen, A. Seber, W. Saber, M. A. Kharfan-Dabaja, W. Rasheed, S. Okamoto, N. Khera, W. A. Wood, M. B. C. Koh, H. Greinix, Y. Kodera, J. Szer, M. M. Horowitz, D. Weisdorf and M. Aljurf	2020	Correction: Worldwide Network for Blood and Marrow Transplantation (W current opportunities and challenges in low- and lower-middle income cou
339	Muhsen, I. N., S. K. Hashmi, D. Niederwieser, N. Kroeger, S. Agrawal, M. C. Pasquini, Y. Atsuta, K. K. Ballen, A. Seber, W. Saber, M. A. Kharfan-Dabaja, W. Rasheed, S. Okamoto, N. Khera, W. A. Wood, M. B. C. Koh, H. Greinix, Y. Kodera, J. Szer, M. M. Horowitz, D. Weisdorf and M. Aljurf	2020	Worldwide Network for Blood and Marrow Transplantation (WBMT) pers opportunities and challenges in low- and lower-middle income countries
340	Müller, H., S. Solari, C. Zuñiga, C. Pedreros, J. Troncoso, C. Morente, R. Ovalle, P. Acosta, T. Chavez and E. Alborno	2008	Immunosuppression with generic tacrolimus and mycophenolate mofetil in
341	Muñoz-Villegas, P., A. Sanchez-Rios, M. G. Quinonez-Alvarado, O. Olvera-Montaño, J. D. Quintana-Hau and L. Baiza-Duran	2021	Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A I
342	Murray, L., A. Arias, J. Li, S. Bhoopathy and I. J. Hidalgo	2016	Innovative in vitro methodologies for establishing therapeutic equivalence
343	Mysler, E., V. F. Azevedo, S. Danese, D. Alvarez, N. Iikuni, B. Ingram, M. Mueller and L. Peyrin-Biroulet	2021	Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Exp
344	Mysler, E., M. Caubet and A. Lizarra	2021	Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
345	Neilan, A. M., R. J. Landovitz, M. H. Le, B. Grinsztejn, K. A. Freedberg, M. McCauley, N. Wattananimitgul, M. S. Cohen, A. L. Ciaranello, M. E. Clement, K. P. Reddy, E. P. Hyle, A. D. Paltiel and R. P. Walensky	2022	Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylax
346	Neumann, I., H. J. Schünemann, L. Bero, G. Cooke, N. Magrini and L. Moja	2021	Global access to affordable direct oral anticoagulants
347	Nicholas, J.	2012	Outsourcing clinical trials
348	Nicolau, C. A., A. Prorock, Y. Bao, Agde Neves-Ferreira, R. H. Valente and J. W. Fox	2018	Revisiting the Therapeutic Potential of Bothrops jararaca Venom: Screenin
349	Niyongere, J., T. E. Welty, M. W. Bell, D. Consalvo, C. Hammond, H. Leung, P. N. Patsalos, M. Ryan, T. Suansanae, D. Zhou and H. Zuellig	2022	Barriers to generic antiepileptic medication use: Results of a global survey b Force
350	Norambuena, X., A. Consolaro, F. Bovis and N. Ruperto	2018	The Chilean Spanish version of the Juvenile Arthritis Multidimensional AS
351	Novo, J. B., M. L. Oliveira, G. S. Magalhães, L. Morganti, I. Raw and P. L. Ho	2010	Generation of polyclonal antibodies against recombinant human glucocere

	Journal
and Clinical Comparability of Biosimilar Etanercept	J Immunol Res
reatments: Physicochemical and Clinical Comparability of Biosimilar	J Immunol Res
from Its Physicochemical and Biological Characterization	Biomed Res Int
	Hand surgery & rehabilitation
cerbation: a randomized, controlled, double-blind study	Arch Argent Pediatr
t of Rheumatology, Gastroenterology, and Dermatology Inflammatory	Curr Rheumatol Rep
ars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature	BioDrugs
l Assessment Report (JAMAR)	Rheumatol Int
l Assessment Report (JAMAR)	Rheumatol Int
Colombia	Biomedica : revista del Instituto Nacional de Salud
lusive disorder be augmented by innovative computerized adjuvant?]	L'Encephale
rosis	Mult Scler
lated quality of life instruments? Review of anchors and methods	Health and quality of life outcomes
	Arq Bras Cardiol
feron Beta (IFN-β) Biosimilar Candidates: Impact of Innate Immune	Aaps j
VBMT) perspective: the role of biosimilars in hematopoietic cell transplant: ntries	Bone Marrow Transplant
pective: the role of biosimilars in hematopoietic cell transplant: current	Bone Marrow Transplant
n renal transplant recipients: preliminary report in Chile	Transplant Proc
Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab	J Exp Pharmacol
	Rev Panam Salud Publica
perience?	Drugs
s	Open Access Rheumatol
is in the United States : A Cost-Effectiveness Analysis	Ann Intern Med
	Bull World Health Organ
	J Natl Cancer Inst
g for Novel Activities Using Connectivity Mapping	Toxins (Basel)
y the International League Against Epilepsy Generic Substitution Task	Epilepsia Open
essment Report (JAMAR)	Rheumatol Int
broxidase produced in Escherichia coli	Mol Biotechnol

## Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	<b>Author</b>	<b>Year</b>	<b>Title</b>
352	Nunn, A. S., E. M. Fonseca, F. I. Bastos, S. Gruskin and J. A. Salomon	2007	Evolution of antiretroviral drug costs in Brazil in the context of free and un
353	Nuske, E. O., M. Morozov and H. Alejandro Serra	2021	The use of GA-RxODE (Genetics Algorithms and Running simulations fro bioequivalence studies
354	Ocaña, J. and J. Muñoz	2019	Controlling type I error in the reference-scaled bioequivalence evaluation
355	Ogura, M., J. M. Sancho, S. G. Cho, H. Nakazawa, J. Suzumiya, G. Tumyan, J. S. Kim, A. Lennard, J. Mariz, N. Ilyin, W. Jurczak, A. Lopez Martinez, O. Samoilova, E. Zhavrid, E. Yañez Ruiz, M. Trneny, L. Popplewell, B. Coiffier, C. Buske, W. S. Kim, S. J. Lee, S. Y. Lee, Y. J. Bae and L. W. Kwak	2018	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in compar burden follicular lymphoma: a randomised, double-blind, parallel-group, p
356	Oliveira, S. N., G. R. Santos, B. F. Glauser, N. V. Capillé, I. N. Queiroz, M. S. Pereira, V. H. Pomin and P. A. Mourão	2015	Structural and functional analyses of biosimilar enoxaparins available in B
357	Oliver, M., D. Georges and C. Prieur	2022	Spatialized epidemiological forecasting applied to Covid-19 pandemic at d
358	Olivera, P., W. J. Sandborn, J. Panés, C. Baumann, G. D'Haens, S. Vermeire, S. Danese and L. Peyrin-Biroulet	2018	Physicians' perspective on the clinical meaningfulness of inflammatory bo Inflammatory Bowel Disease (IOIBD) survey
359	Ortiz-Brizuela, E., A. Rangel-Cordero, A. Ponce-de-León and J. Sierra-Madero	2019	False-positive results in the galactomannan Platelia™ Aspergillus assay w
360	Paek, K., G. W. Kim, S. Y. Ahn, J. H. Lim, D. Jung, S. Kim and J. H. Lee	2019	Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab
361	Pagani, E.	2019	Why are biosimilars much more complex than generics?
362	Pallares, C. J. and E. Martínez	2014	[Mortality risk factors associated with healthcare infections in a tertiary lev
363	Palma-Aguirre, J. A., M. Lopez-Gamboa, L. Cariño, V. Burke-Fraga and M. González-de la Parra	2010	Relative bioavailability of two oral formulations of piroxicam 20 mg: a sim comparison in healthy Mexican adult volunteers
364	Palmer, J. L., A. Kunhihtlu, A. Costantini, F. Esquivel, J. Roush, K. Edwards and T. W. Hill	2014	Pharmacokinetic bioequivalence crossover study of branded generic and in
365	Park, W., L. Božić-Majstorović, D. Milakovic, A. Berrocal Kasay, E. C. El-Khouri, F. Irazoque-Palazuelos, F. F. C. Molina, P. Shesternya, P. Miranda, F. G. Medina-Rodríguez, P. Wiland, S. Jeka, J. Chavez-Corrales, O. Garmish, T. Linde, D. Rekalov, P. Hrycaj, A. Krause, N. Fomina, O. Piura, M. Abello-Banfí, C. H. Suh, S. C. Shim, S. J. Lee, S. Y. Lee, S. H. Kim and D. H. Yoo	2018	Comparison of biosimilar CT-P10 and innovator rituximab in patients with
366	Park, W., C. H. Suh, S. C. Shim, F. F. C. Molina, S. Jeka, F. G. Medina-Rodríguez, P. Hrycaj, P. Wiland, E. Y. Lee, P. Shesternya, V. Kovalenko, L. Myasoutova, M. Stanislav, S. Radominski, M. J. Lim, J. Y. Choe, S. J. Lee, S. Y. Lee, S. H. Kim and D. H. Yoo	2017	Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar Week Open-Label Study in Patients with Rheumatoid Arthritis
367	Park, W., D. H. Yoo, J. Jaworski, J. Brzezicki, A. Gnylorybov, V. Kadinov, I. G. Sariego, C. Abud-Mendoza, W. J. Escalante, S. W. Kang, D. Andersone, F. Blanco, S. S. Hong, S. H. Lee and J. Braun	2016	Comparable long-term efficacy, as assessed by patient-reported outcomes, with ankylosing spondylitis: 54-week results from the randomized, paralle
368	Park, W., D. H. Yoo, P. Miranda, M. Brzosko, P. Wiland, S. Gutierrez-Ureña, H. Mikazane, Y. A. Lee, S. Smiyani, M. J. Lim, V. Kadinov, C. Abud-Mendoza, H. Kim, S. J. Lee, Y. Bae, S. Kim and J. Braun	2017	Efficacy and safety of switching from reference infliximab to CT-P13 com from the PLANETAS extension study
369	Parrillo-Campiglia, S., M. C. Ercoli, O. Umpierrez, P. Rodríguez, S. Márquez, C. Guarneri, F. T. Estevez-Parrillo, M. Laurenz and F. E. Estevez-Carrizo	2009	Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a crossover comparison in healthy male South American volunteers
370	Pasqualini, A., C. Ruhlmann, G. A. Botti, D. E. Estofán, S. Pasqualini, F. Inciarte, F. Ruhlmann, C. Lopez, C. Palena, E. Klimovsky, A. Federico, E. Gonzalez, L. Cordeiro and N. Lago	2021	Efficacy, safety, and immunogenicity of a biosimilar recombinant human f ovarian stimulation for IVF: A randomized, multicenter, evaluator-blinded
371	Patel, R., J. L. Palmer, S. Joshi, A. Di Cío Gimena and F. Esquivel	2017	Pharmacokinetic and Bioequivalence Studies of a Newly Developed Brand
372	Patil, U., A. Goyal, B. Vu, Y. Liu, V. Maranholkar, K. Kourentzi, J. M. Briggs and R. C. Willson	2021	Antibody mix-and-read assays based on fluorescence intensity probes
373	Pedersen, M. K., G. Meyer and L. Uhrenfeldt	2017	Risk factors for acute care hospital readmission in older persons in Western
374	Pegram, M. D., I. Bondarenko, M. M. C. Zorzetto, S. Hingmire, H. Iwase, P. V. Krivorotko, K. S. Lee, R. K. Li, J. Pikiel, R. Aggarwal, R. Ewesuedo, A. Freyman, R. Li, A. Vana, D. Yin, C. Zacharchuk and E. Tan-Chiu	2019	PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with ref cancer: a randomised, double-blind study
375	Peliçário Vargas, B., M. H. M. Sari and L. M. Ferreira	2022	Trastuzumab in Breast Cancer Treatment: The Era of Biosimilars
376	Peñarrieta-de Córdoba, I., F. F. Barrios, T. Gutierrez-Gomes, S. Piñonez-Martinez Mdel, L. M. Quintero-Valle and H. Castañeda-Hidalgo	2014	Self-management in chronic conditions: partners in health scale instrumen

	Journal
Universal access to AIDS treatment	PLoS Med
from Ordinary Differential Equations-based model) method to optimize	Pharmacol Res Perspect
of highly variable drugs	Pharm Stat
Comparison with rituximab in patients with previously untreated low-tumour-stage 3 trial	Lancet Haematol
Brazil	Thromb Haemost
Departmental scale in France	Systems & control letters
Low-dose trial results: an International Organization for the Study of	Aliment Pharmacol Ther
with generic piperacillin/tazobactam	Rev Iberoam Micol
of Biosimilar	BioDrugs
	Einstein (Sao Paulo)
level university hospital in Colombia]	Biomedica
single-dose, randomized-sequence, open-label, two-period crossover	Clin Ther
Innovator formulations of the cholesterol lowering agent ezetimibe	Clin Pharmacol Drug Dev
in rheumatoid arthritis: a randomized controlled Phase 3 trial	MAbs
CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-	BioDrugs
on safety and pharmacokinetics, of CT-P13 and reference infliximab in patients in the PLANETAS study	Arthritis Res Ther
Compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data	Ann Rheum Dis
randomized, open-label, single-dose, fasting, two-period, two-sequence	Clinical therapeutics
of follicle-stimulating hormone (Folitime®) vs. Gonaf® in women undergoing IVF, non-inferiority study	JBRA Assist Reprod
of Generic of Candesartan Cilexetil Tablets in Healthy Volunteers	Clin Pharmacol Drug Dev
	MAbs
in countries: a systematic review	JBIC database of systematic reviews and implementation reports
Comparison of trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer	Br J Cancer
	Anticancer Agents Med Chem
of validation	Nursing management (Harrow, London, England : 1994)

Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	Author	Year	Title
377	Pépin, J. L., J. F. Muir, T. Gentina, Y. Dauvilliers, R. Tamisier, M. Sapene, P. Escourrou, B. Fleury, F. Philip-Joet, P. Philip and M. P. d'Ortho	2009	Pressure reduction during exhalation in sleep apnea patients treated by con
378	Pequeno, N. P. F., N. L. A. Cabral, D. M. Marchioni, Sevc Lima and C. O. Lyra	2020	Quality of life assessment instruments for adults: a systematic review of po
379	Perazzo, H., R. Castro, P. M. Luz, M. Banholi, R. V. Goldenzon, S. W. Cardoso, B. Grinsztejn and V. G. Veloso	2020	Effectiveness of generic direct-acting agents for the treatment of hepatitis
380	Pérez-Quintanilla, M., R. Méndez-Martínez, S. Vázquez-Vega, R. Espinosa-Romero, R. Sotelo-Regil, M. D. Pérez-Montiel, U. Ramos-Alamillo, T. J. Cabrera-López, S. A. Barquet-Muñoz, C. Pérez-Plascencia, A. García-Carrancá and D. Cantú de León	2020	High prevalence of human papillomavirus and European variants of HPV
381	Perini, G. F., C. C. P. Feres, L. L. C. Teixeira and N. Hamerschlak	2021	BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia
382	Petan, J. A., N. Undre, M. R. First, K. Saito, T. Ohara, O. Iwabe, H. Mimura, M. Suzuki and S. Kitamura	2008	Physicochemical properties of generic formulations of tacrolimus in Mexico
383	Petrelli, F., A. Caraffa, S. Scuri, I. Grappasonni, E. Magrini and A. Cocchini	2019	The requirements for manufacturing highly active or sensitising drugs com
384	Pharmaceutical Works Polpharma, S. A.	2021	A PHASE III, MULTICENTRE, RANDOMISED, INVESTIGATOR-MADE STUDY OF GENERIC LATANOPROST + TIMOLOL (50µG + 5MG)/ML EYE DROPS COMPARED TO XALACOM® (LATANOPROST 0.005 % OPHTHALMIC SOLUTION) AND XALATAN® (LATANOPROST 0.005 % OPHTHALMIC SOLUTION) WITH OCULAR HYPERTENSION OR PRIMARY OPEN ANGLE GLAUCOMA. A generi szemcsepp (Polpharma S.A.) és a Xalacom® (latanoproszt 0,005% és timolol multicentrikus, randomizált, a vizsgáló előtt maszkolt, keresztezett, összehasonlító, non-inferioritási vizsgálata emelkedett szemelnyomású v
385	Picon, P. D., S. C. Pribbernow, C. A. Prompt, S. C. Schacher, V. V. Antunes, B. P. Mentz, F. L. Oliveira, C. M. Souza and F. C. Schacher	2014	Randomized double-blind clinical trial of a new human epoetin versus a co
386	Pimentel, F. F., G. Morgan, D. G. Tiezzi and J. M. de Andrade	2018	Development of New Formulations of Biologics: Expectations, Immunoge
387	Pineda, C., G. Castañeda Hernández, I. A. Jacobs, D. F. Alvarez and C. Carini	2016	Assessing the Immunogenicity of Biopharmaceuticals
388	Piñeyro-López, A., E. Piñeyro-Garza, M. Gómez-Silva, R. Reyes-Araiza, M. A. Flores-Diego, S. Borrego-Alvarado, M. E. Gamino-Peña, R. Vargas-Zapata and M. E. Salazar-Leal	2009	Bioequivalence of single 100-mg doses of two oral formulations of topiramate in healthy adult male Mexican volunteers
389	Piñeyro-López, A., E. Piñeyro-Garza, O. Torres-Alanis, R. Reyes-Araiza, M. Gómez Silva, N. Wacksman, R. Luján Rangel, A. de Lago, D. Trejo, M. González-de la Parra and S. Namur	2006	Bioavailability of two oral formulations of loratadine 20 mg with concomitant comparison in healthy Mexican adult volunteers
390	Piñeyro-López, A., E. Piñeyro-Garza, O. Torres-Alanis, R. Reyes-Araiza, M. Gómez Silva, N. Wacksman, R. L. Rangel, A. de Lago, M. González-de la Parra and S. Namur	2005	Bioavailability of two oral formulations of azithromycin 500 mg: a random subjects
391	Piñeyro-López, A., E. Piñeyro-Garza, O. Torres-Alanis, R. Reyes-Araiza, M. Gómez-Silva, N. Waksman, E. Salazar-Leal M and R. Luján-Rangel	2007	Evaluation of the bioequivalence of single 100-mg doses of two oral formulations period crossover study in healthy adult male Mexican volunteers
392	Pinheiro, E., A. Vasan, J. Y. Kim, E. Lee, J. M. Guimier and J. Perriens	2006	Examining the production costs of antiretroviral drugs
393	Pinto, A. P., N. F. Schlecht, J. Pintos, J. Kaiano, E. L. Franco, C. P. Crum and L. L. Villa	2004	Prognostic significance of lymph node variables and human papillomavirus
394	Pinto, V. F., M. A. Moretti and A. C. Chagas	2010	[Critical analysis of criteria for the evaluation of low-molecular weight heparin
395	Poddubnaya, I. V., S. M. Alekseev, K. D. Kaplanov, L. M. Lukavetsky, G. B. Rekhman, T. K. Dolai, V. S. S. Attili, C. D. Bermúdez, A. A. Isaev, E. V. Chernyaeva and R. A. Ivanov	2020	Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment multicenter randomized trial
396	Polpharma, S. A.	2018	A PHASE III, MULTICENTRE, RANDOMISED, INVESTIGATOR-MADE STUDY OF GENERIC LATANOPROST + TIMOLOL (50µG + 5MG)/ML EYE DROPS COMPARED TO XALATAN® (LATANOPROST 0.005 % OPHTHALMIC SOLUTION) AND XALACOM® (LATANOPROST 0.005 % OPHTHALMIC SOLUTION) WITH OCULAR HYPERTENSION OR PRIMARY OPEN ANGLE GLAUCOMA. A generi szemcsepp (Polpharma S.A.) és a Xalacom® (latanoproszt 0,005% és timolol multicentrikus, randomizált, a vizsgáló előtt maszkolt, keresztezett, összehasonlító, non-inferioritási vizsgálata emelkedett szemelnyomású v
397	Pompei, C. M. E., L. Ciric, M. Canales, K. Karu, E. M. Vieira and L. C. Campos	2017	Influence of PPCPs on the performance of intermittently operated slow sar
398	Poo, J. L., J. F. Galán, A. Rosete, A. de Lago, I. Oliva, M. González-de la Parra, P. Jiménez, V. Burke-Fraga and S. Namur	2008	Bioavailability of two single-dose oral formulations of omeprazole 20 mg: comparison in healthy Mexican adult volunteers

	Journal
tinuous positive airway pressure	Chest
population-based studies	Health and quality of life outcomes
C: systematic review and meta-analysis	Bull World Health Organ
16 infecting concomitantly to cervix and oral cavity in HIV positive women	PloS one
	Curr Treat Options Oncol
	Transplant Proc
Comparing Good Manufacturing Practices	Acta Biomed
SKED, CROSS-OVER, COMPARATIVE, NON-INFERIORITY TRIAL DROPS, SOLUTION (POLPHARMA S.A.) COMPARED TO & TIMOLOL 0.5% FIXED COMBINATION, PFIZER) IN PATIENTS UCOMA. A generikus latanoproszt + timolol (50 µg + 5 mg)/ml oldatos timolol 0,5% fix kombinációs oldatos szemcsepp, Pfizer) III. fázisú, hasonlító, non-inferioritási vizsgálata emelkedett szemelnyomású vagy	EU Clinical Trials Register
commercially available formula for anemia control in patients on hemodialysis	Clinics (Sao Paulo)
enicity, and Safety for Subcutaneous Trastuzumab	Pharmaceut Med
	BioDrugs
mate: an open-label, randomized-sequence, two-period crossover study in	Clin Ther
tant ketoconazole: an open-label, randomized, two-period crossover	Clinical therapeutics
nized, open-label, two-period crossover comparison in healthy Mexican adult	Clinical therapeutics
ulations of cyclosporin A microemulsion: a randomized, open-label, two-	Clinical therapeutics
	Aids
s DNA in invasive vulvar carcinoma	Gynecologic oncology
parin biosimilars]	Arq Bras Cardiol
reatment of patients with indolent non-Hodgkin lymphomas: An international	Hematol Oncol
SKED, CROSSOVER, COMPARATIVE, NON-INFERIORITY TRIAL LATANOPROST 0.05 MG/ML EYE DROPS SOLUTION (POLPHARMA ALMIC SOLUTION, PFIZER) IN PATIENTS WITH OCULAR rikus latanoprost 0,05 mg/ml oldatos szemcsepp (Polpharma S.A.) és a icentrikus, randomizált, a vizsgáló előtt maszkolt, keresztezett, agy primer nyílt zugú glaucomában szenvedő betegeknél	EU Clinical Trials Register
nd filters for household water purification	Sci Total Environ
an open-label, randomized sequence, two-period crossover comparison in	Clinical therapeutics

Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	Author	Year	Title
399	Pouillon, L., S. Danese, A. Hart, G. Fiorino, M. Argollo, C. Selmi, C. Carlo-Stella, D. Loeuille, A. Costanzo, A. Lopez, E. Vegni, S. Radice, D. Gilardi, M. Socha, M. Fazio, M. González-Lorenzo, S. Bonovas, F. Magro and L. Peyrin-Biroulet	2019	Consensus report: clinical recommendations for the prevention and management of inflammatory bowel disease
400	Prachniak-Rincón, C. and J. Villar de Onís	2016	HIV and the Right to Health in Colombia
401	Pron, G., L. Ieraci, K. Kaulback and Health Quality Ontario Medical Advisory Secretariat	2011	Collagen cross-linking using riboflavin and ultraviolet-a for corneal thinning
402	Prync, A. E., P. Yankilevich, P. R. Barrero, R. Bello, L. Marangunich, A. Vidal, M. Criscuolo, L. Benasayag, A. L. Famulari, R. O. Domínguez, M. A. Kauffman and R. A. Diez	2008	Two recombinant human interferon-beta 1a pharmaceutical preparations prepared by microarray analysis
403	Qneibi, D., E. Ramacciotti, A. S. Macedo, R. A. Caffaro, L. B. Agati, F. Siddiqui, A. Kouta, D. Hoppensteadt, J. Fareed and C. A. Carter	2020	Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and its Biosimilar
404	Rahalkar, H., H. C. Cetintas and S. Salek	2018	Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibodies: Regulatory Guidelines
405	Raimondo, N., C. Echeverría, F. Stengel, G. Pellerano, J. Kreimer, L. Mazzuocolo, M. Maskin, N. Kogan, P. Luna and S. Gusis	2018	[Biosimilars: Expert consensus of the Latin American Society of Psoriasis and Dermatology]
406	Ramacciotti, E., U. Ferreira, A. J. V. Costa, S. R. O. Raymundo, J. A. Correa, S. G. Neto, A. B. Osvaldt, L. Agati, V. C. R. Aguiar, R. Davila, T. B. Caltabiano, F. M. Magella, G. G. Volpiani, V. Castelli, Jr., R. A. Caffaro, L. Z. DalAcqua, W. E. Matheus, D. Y. Sato, Gjds Russeff, D. G. de Souza, L. E. Pazetto, T. A. M. de Lima, Emds Colnago, E. Y. Fugii, J. S. Mussalem, V. T. Assao, O. Toffoletto, D. G. Rodrigues, J. B. Afiane and G. R. Araujo	2018	Efficacy and Safety of a Biosimilar Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism: A Randomized, Prospective, Single-Blinded, Multicenter Clinical Trial
407	Ramos, M. B., A. E. V. Araújo, C. P. Pestana, A. P. D. Ano Bom, R. C. Bastos, A. de Almeida Oliveira, P. C. da Costa Neves and H. C. da Silva Junior	2020	Initial development of biosimilar immune checkpoint blockers using HEK293T cells
408	Rat, C., C. Pogu, D. Le Donné, C. Latour, G. Bianco, F. Nanin, A. Cowppli-Bony, A. Gaultier and J. M. Nguyen	2017	Effect of Physician Notification Regarding Nonadherence to Colorectal Cancer Screening: A Randomized Clinical Trial
409	Ravelli, A., A. Consolaro, G. Horneff, R. M. Laxer, D. J. Lovell, N. M. Wulffraat, J. D. Akikusa, S. M. Al-Mayouf, J. Antón, T. Avcin, R. A. Berard, M. W. Beresford, R. Burgos-Vargas, R. Cimaz, F. De Benedetti, E. Demirkaya, D. Foell, Y. Itoh, P. Lahdenne, E. M. Morgan, P. Quartier, N. Ruperto, R. Russo, C. Saad-Magalhães, S. Sawhney, C. Scott, S. Shenoj, J. F. Swart, Y. Uziel, S. J. Vastert and J. S. Smolen	2018	Treating juvenile idiopathic arthritis to target: recommendations of an international consensus
410	Reaney, M. D., C. Martin and J. Speight	2008	Understanding and Assessing the Impact of Alcoholism on Quality of Life: A Systematic Review and Meta-Analysis
411	Redfern, J., H. Kaur, R. A. Adedoyin, S. Ofori, R. Anchala, A. S. Vamadevan, L. De Andrade, J. Zelaya, D. Balabanova and M. U. Sani	2019	Equivalence in Active Pharmaceutical Ingredient of Generic Antihypertensive Drugs: A Systematic Review and Meta-Analysis
412	Reinmuth, N., M. Bryl, I. Bondarenko, K. Syrigos, V. Vladimirov, M. Zereu, A. H. Bair, F. Hilton, K. Liao and K. Kasahara	2019	PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
413	Renois, F., D. Talmud, A. Huguénin, L. Moutte, C. Strady, J. Cousson, N. Lévêque and L. Andréoletti	2010	Rapid detection of respiratory tract viral infections and coinfections in patients with asthma using microarray systems
414	Resende, H. M., L. Ladislau, A. C. F. Cardoso, J. D. P. Brandão, B. R. Assis, P. Cardoso, P. H. A. Marassi and V. Castilho	2021	Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists
415	Revilla Beltri, J.	2013	Response to "Potential Regulatory and Commercial Environment for Biosimilars"
416	Reychler, G., G. Caty, A. Vincent, S. Billo and J. C. Yombi	2013	Validation of the French version of the World Health Organization quality of life questionnaire
417	Reyes-Beltrán, B. and G. Delgado	2017	Anti-drug antibodies in Colombian patients with rheumatoid arthritis treated with tocilizumab
418	Ribeiro, T. B., A. Ribeiro, L. O. Rodrigues, G. Harada and M. R. C. Nobre	2020	U.S. Food and Drug Administration anticancer drug approval trends from 2010 to 2019
419	Riva, N., P. C. Guido, J. Ibañez, N. Licciardone, M. Rousseau, G. Mato, M. Monteverde and P. Schaiquevich	2014	Therapeutic monitoring of pediatric renal transplant patients with conversion of tacrolimus to its active form
420	Riva, N., M. Molina, B. L. Cornaló, M. V. Salvador, A. Savransky, S. Tenenbaum, M. M. Katsicas, M. Monteverde, P. Cáceres Guido, M. Rousseau, R. Staciuk, A. González Correas, P. Zubizarreta, O. Imventarza, E. Lagomarsino, E. Spitzer, M. Tinelli and P. Schaiquevich	2021	Intensive Safety Monitoring of Rituximab (Biosimilar Novex®) and the Impact on Clinical Outcomes in Rheumatoid Arthritis
421	Rivera, V. M.	2019	Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a New Opportunity?
422	Rivera, V. M. and M. A. Macias	2017	Access and barriers to MS care in Latin America

	Journal
ement of the nocebo effect in biosimilar-treated IBD patients	Aliment Pharmacol Ther
	Health Hum Rights
ng disorders: an evidence-based analysis	Ontario health technology assessment series
roduce a similar transcriptional response determined using whole genome	Int J Clin Pharmacol Ther
and a New Biosimilar Version	Clin Appl Thromb Hemost
nal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM	Front Pharmacol
(SOLAPSO) in Argentina]	Medicina (B Aires)
vention of Venous Thromboembolism Following Major Abdominal Surgery:	Clin Appl Thromb Hemost
293 cells	Protein Expr Purif
ancer Screening on Patient Participation in Fecal Immunochemical Test	JAMA
ernational task force	Ann Rheum Dis
A Systematic Review of the Content Validity of Instruments Used to	The patient
ive Medicines Available in Nigeria (EQUIMEDS): A Case for Further	Glob Heart
acizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Randomized, Double-Blind Study	BioDrugs
ients with influenza-like illnesses by use of reverse transcription-PCR DNA	Journal of clinical microbiology
n Oncologists' Opinions, Practices, and Concerns	JCO Glob Oncol
similar in Latin America" by Azevedo et al	Value Health Reg Issues
of life HIV instrument	PloS one
ed with Enbrel vs Etaner - Preliminary report	J Immunotoxicol
2016 to 2018 for lung, colorectal, breast, and prostate cancer	Int J Technol Assess Health Care
on to generic cyclosporin	Int J Clin Pharm
nnovator) in Pediatric Patients With Complex Diseases	Front Pharmacol
a Regulatory Risk?	Neurol Ther
	Mult Scler J Exp Transl Clin



Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	Author	Year	Title
423	Riverro-Serrano, O., M. Juan-Lopez, F. Lerdo-de Tejada, M. A. Montoya-Cabrera, R. Camacho-Solis, F. Valenzuela-Gomez Gallardo, A. Lifshitz, J. Gamboa-Marrufo and M. Martínez-Domínguez	1998	[Generics as therapeutic resources]
424	Rodrigues, P. H. A., Rdfdc Silva and C. Kiss	2022	[Recent changes and continuity of technological and economic dependency]
425	Rodrigues, W. C. and O. Soler	2009	[Compulsory licensing of efavirenz in Brazil in 2007: contextualization]
426	Rodriguez, C. A., M. Agudelo, Y. A. Aguilar, A. F. Zuluaga and O. Vesga	2016	Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics
427	Rodriguez, C. A., M. Agudelo, J. C. Cataño, A. F. Zuluaga and O. Vesga	2009	Potential therapeutic failure of generic vancomycin in a liver transplant pa
428	Rodriguez, C. A., M. Agudelo, A. F. Zuluaga and O. Vesga	2010	In vitro and in vivo comparison of the anti-staphylococcal efficacy of gene
429	Rodriguez, C. A., M. Agudelo, A. F. Zuluaga and O. Vesga	2012	Generic vancomycin enriches resistant subpopulations of Staphylococcus s
430	Rodriguez, C. A., M. Agudelo, A. F. Zuluaga and O. Vesga	2015	Impact on resistance of the use of therapeutically equivalent generics: the c
431	Rodriguez, C. A., M. Agudelo, A. F. Zuluaga and O. Vesga	2017	In vivo pharmacodynamics of piperacillin/tazobactam: implications for an
432	Rodriguez, N., M. Grosso, B. Galvez, G. Calderon, L. Lau, V. A. Turner and I. J. Hidalgo	2021	Evaluation of the In-Vitro Dissolution Permeation Systems 1 (IDAS1) as a
433	Rodríguez, S., A. Muñoz, R. H. Bustos and D. Jaimes	2020	Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse
434	Rodríguez-Carranza, R., H. Vidrio, P. Vilar-Puig and E. Díaz-Jouanen	2000	[Generic drugs and medical education]
435	Rojo, P.	2001	[Access to essential drugs in developing countries]
436	Rolando, R. F., Sd Silva, R. H. Peralta, A. J. Silva, S. Cunha Fde, A. R. Bello and J. M. Peralta	2012	Detection and differentiation of Cryptosporidium by real-time polymerase
437	Rombini, F., D. M. Cecchini, J. Ballivian, M. Huberman, A. Urueña and I. Cassetti	2021	Dual therapy with raltegravir plus a fixed dose combination of darunavir/r
438	Romera, A., S. Peredpaya, Y. Shparyk, I. Bondarenko, G. Mendonça Bariani, K. C. Abdalla, E. Roca, F. Franke, F. Melo Cruz, A. Ramesh, V. Ostwal, P. Shah, S. A. Rahuman, A. Paravisini, C. Huerga, A. Del Campo García and S. Millán	2018	Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combi
439	Roost, M. S., H. Potthast, C. Walther, A. García-Arieta, I. Abalos, E. Agostinho Freitas Fernandes, G. Mendes Lima Santos, Z. Rodríguez Martínez, A. Tam, C. Rodrigues, D. A. Gutierrez Triana, E. Guzmán Aurela, N. Rodríguez Rodríguez, S. Aeh Park, J. Kim, R. Kariv, M. Divinsky, B. Jones, R. Kuribayashi, A. Myoenzono, M. Kasuga, J. Van Oudtshoorn, J. F. Chi, W. Y. Hung, L. F. Hsu, C. Crane, T. Jarman and A. Braddy	2021	Requirements for Additional Strength Biowaivers for Modified Release Sc
440	Rosales-Mendoza, S., K. I. Solís-Andrade, V. A. Márquez-Escobar, O. González-Ortega and B. Bañuelos-Hernandez	2020	Current advances in the algae-made biopharmaceuticals field
441	Rouillon, F., G. Berdeaux, J. C. Bisserbe, B. Warner, M. Mesbah, C. Smadja and J. Chwalow	2000	Prevention of recurrent depressive episodes with milnacipran: consequenc
442	Rozo-Lopez, P. and X. Mengual	2015	Updated list of the mosquitoes of Colombia (Diptera: Culicidae)
443	Rugo, H. S., A. Barve, C. F. Waller, M. Hernandez-Bronchud, J. Herson, J. Yuan, R. Sharma, M. Baczkowski, M. Kothekar, S. Loganathan, A. Manikhas, I. Bondarenko, G. Mukhametshina, G. Nemsadze, J. D. Parra, M. L. Abesamis-Tiambeng, K. Baramidze, C. Akewanlop, I. Vynnychenko, V. Sriuranpong, G. Mamillapalli, S. Roy, E. P. Yanez Ruiz and E. Pennella	2017	Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab
444	Rugo, H. S., E. J. Pennella, U. Gopalakrishnan, M. Hernandez-Bronchud, J. Herson, H. F. Koch, S. Loganathan, S. Deodhar, A. Marwah, A. Manikhas, I. Bondarenko, G. Mukhametshina, G. Nemsadze, J. D. Parra, M. L. T. Abesamis-Tiambeng, K. Baramidze, C. Akewanlop, I. Vynnychenko, V. Sriuranpong, G. Mamillapalli, S. Roy, E. P. Yanez Ruiz, A. Barve, A. Fuentes-Alburo and C. F. Waller	2021	Final overall survival analysis of the phase 3 HERITAGE study demonstra
445	Rugo, H. S., E. J. Pennella, U. Gopalakrishnan, M. Hernandez-Bronchud, J. Herson, H. F. Koch, S. Loganathan, S. Deodhar, A. Marwah, A. Manikhas, I. Bondarenko, J. D. Parra, M. L. T. Abesamis-Tiambeng, C. Akewanlop, I. Vynnychenko, V. Sriuranpong, S. Roy, E. P. Yanez Ruiz, A. Barve and C. F. Waller	2021	Correlation between week 24 trastuzumab-dkst response and week 48 prog
446	Ruiz, M. E., P. Conforti, P. Fagiolino and M. G. Volonté	2010	The use of saliva as a biological fluid in relative bioavailability studies: co

	Journal
	Gac Med Mex
y in the pharmaceutical industry in Brazil]	Cad Saude Publica
	Revista panamericana de salud publica = Pan American journal of public health
: The Case of Piperacillin-Tazobactam	PLoS One
patient with MRSA peritonitis and bacteremia	J Infect
eric products and the innovator of oxacillin	BMC Infect Dis
aureus after exposure in a neutropenic mouse thigh infection model	Antimicrob Agents Chemother
case of ciprofloxacin	Antimicrob Agents Chemother
antimicrobial efficacy and resistance suppression with innovator and generic	Int J Antimicrob Agents
a potential tool to monitor for unexpected changes in generic medicaments in	Eur J Pharm Sci
e Events, Evolution, and Perspective: An Overview	Biomedicines
	Gac Med Mex
	Gac Sanit
chain reaction in stool samples from patients in Rio de Janeiro, Brazil	Memorias do Instituto Oswaldo Cruz
itonavir in people living with HIV in Argentina	Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia
ation with FOLFOX or FOLFIRI as first-line treatment for metastatic	Lancet Gastroenterol Hepatol
olid Oral Dosage Forms in International Pharmaceutical Regulators Commonalities	J Pharm Pharm Sci
	Expert Opin Biol Ther
es on quality of life	Journal of affective disorders
	Biodiversity data journal
o on Overall Response Rate in Patients With ERBB2 (HER2)-Positive	Jama
tes equivalence of trastuzumab-dkst to trastuzumab in HER2-positive	Breast Cancer Res Treat
gression-free survival: the HERITAGE trial	Breast
mparison and correlation with plasma results	Biopharm Drug Dispos

## Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	Author	Year	Title
447	Ruiz Picazo, A., M. T. Martinez-Martinez, S. Colón-Useche, R. Iriarte, B. Sánchez-Dengra, M. González-Álvarez, A. García-Arieta, I. González-Álvarez and M. Bermejo	2018	In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-
448	Ruiz-Argüelles, G. J., A. Seber and G. J. Ruiz-Delgado	2022	Conducting hematopoietic stem cell transplantation in low and middle income
449	Ruperto, N., H. I. Brunner, P. Quartier, T. Constantin, N. M. Wulfraat, G. Horneff, O. Kasapcopur, R. Schneider, J. Anton, J. Barash, R. Berner, F. Corona, R. Cuttica, M. Fouillet-Desjonqueres, M. Fischbach, H. E. Foster, D. Foell, S. C. Radominski, A. V. Ramanan, R. Trauzeddel, E. Unsal, J. Levy, E. Vritzali, A. Martini and D. J. Lovell	2018	Canakinumab in patients with systemic juvenile idiopathic arthritis and active phase III pivotal trials
450	Rutten-van Mólken, M. P., J. B. Oostenbrink, D. P. Tashkin, D. Burkhart and B. U. Monz	2006	Does quality of life of COPD patients as measured by the generic EuroQoL
451	Rwagitivitywa, J., M. Lapeyre-Mestre, R. Bourrel and A. Sommet	2018	Generic antiretroviral drug use in HIV-infected patients: A cohort study from
452	Saavedra, I., E. Tamayo, A. Gamboa, J. Sasso, N. Varela, I. Moreno, D. Marchant, D. Cáceres and L. Quiñones	2010	Relative bioavailability study with two oral formulations of topiramate using
453	Salguero, E., D. Plaza, A. Mariño, C. Moreno and G. Delgado	2009	Characterising vancomycin's immunotoxic profile using Swiss and CFW models
454	Salinas Rebolledo, Elizabeth Angélica, Francisco Chiaravalloti Neto and Leandro Luiz Giatti	2018	Experiencias, beneficios y desafíos del uso de geoprocamiento para el desarrollo
455	Salinas-Jazmín, N., E. González-González, L. X. Vásquez-Boehm, S. M. Pérez-Tapia and M. A. Velasco-Velázquez	2017	In Vitro Methods for Comparing Target Binding and CDC Induction Between
456	Sanabria, E.	2014	The same thing in a different box: similarity and difference in pharmaceutical
457	Sancllemente, G., R. Murphy, J. Contreras, H. García and X. Bonfill Cosp	2015	Anti-TNF agents for paediatric psoriasis
458	Santos da Silva, André, Gabriella de Alcantara Maciel, Luciane Soares de Lima Wanderley and Almir Gonçalves Wanderley	2017	Indicadores do uso de medicamentos na atenção primária de saúde: uma revisão
459	Santos, Vd and S. M. Nitri	2004	[Prescription and patient-care indicators in healthcare services]
460	Santos-Neto, J. F., F. O. Oliveira, K. V. S. Hodel, L. M. S. Fonseca, R. Badaró and B. A. S. Machado	2021	Technological Advancements in Monoclonal Antibodies
461	Scheinberg, M.	2014	Biosimilars in Crohn's disease
462	Scheinberg, M.	2015	Therapy: Facing up to biosimilar agents--the ACR position
463	Scheinberg, M. and V. Azevedo	2019	The future landscape of biosimilars in rheumatology: Where we are where
464	Scheinberg, M. and J. J. Gomez-Reino	2016	Therapy: The NICE position on indications for biologics and biosimilars
465	Scheinberg, M. A. and V. F. Azevedo	2014	Biosimilars in rheumatology: perspective and concerns
466	Scheinberg, M. A. and J. Kay	2012	The advent of biosimilar therapies in rheumatology--"O brave new world"
467	Schwanke, R. C., G. Renard, J. M. Chies, M. M. Campos, E. L. Batista, Jr., D. S. Santos and L. A. Basso	2009	Molecular cloning, expression in Escherichia coli and production of bioactive stimulating factor
468	Sharma, S., C. Bowman, B. Alladin-Karan and N. Singh	2016	Antibiotic prescribing patterns in the pediatric emergency department at G
469	Shim, S. C., L. Božić-Majstorović, A. Berrocal Kasay, E. C. El-Khoury, F. Irazoque-Palazuelos, F. F. Cons Molina, F. G. Medina-Rodríguez, P. Miranda, P. Shesternya, J. Chavez-Corrales, P. Wiland, S. Jeka, O. Garmish, P. Hrycaj, N. Fomina, W. Park, C. H. Suh, S. J. Lee, S. Y. Lee, Y. J. Bae and D. H. Yoo	2019	Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheu
470	Silva, André Santos da, Gabriella de Alcantara Maciel, Luciane Soares de Lima Wanderley and Almir Gonçalves Wanderley	2017	Drug use indicators in primary health care: a systematic review
471	Silva, E. S., R. S. Pacheco, C. M. Gontijo, I. R. Carvalho and R. P. Brazil	2002	Visceral leishmaniasis caused by Leishmania (Viannia) braziliensis in a pa
472	Silva, K. C., M. L. Rosa, N. Moyse, L. A. Afonso, L. H. Oliveira and S. M. Cavalcanti	2009	Risk factors associated with human papillomavirus infection in two popula
473	Silva Mde, F., S. G. Schramm, E. K. Kano, E. E. Mori Koono, V. Porta and C. H. dos Reis Serra	2010	Bioequivalence evaluation of single doses of two tramadol formulations: a volunteers
474	Silva, T. B. C., Phrf Almeida, V. E. Araújo, F. A. Acurcio, A. A. Guerra Júnior, B. Godman and J. Alvares	2018	Effectiveness and safety of insulin glargine versus detemir analysis in patie
475	Silvério, M. S. and I. C. Leite	2010	[Quality of prescriptions in a city of Minas Gerais: a pharmacoepidemiology
476	Silvestre, A. L. P., J. A. Oshiro-Júnior, C. Garcia, B. O. Turco, J. M. da Silva Leite, B. P. G. de Lima Damasceno, J. C. M. Soares and M. Chorilli	2021	Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strate

	Journal
Step IVIVC	Mol Pharm
ome countries	Hematology
ive systemic features: results from the 5-year long-term extension of the	Ann Rheum Dis
five-dimension questionnaire differentiate between COPD severity stages?	Chest
om the French health insurance database	Therapie
ng a validated UPLC-MS/MS method	Int J Clin Pharmacol Ther
nice as an experimental model	Biomed Pharmacother
esarrollo de la atención primaria de salud	Revista Panamericana de Salud Publica
een Therapeutic Antibodies: Applications in Biosimilarity Analysis	J Vis Exp
ical sex hormone consumption and marketing	Med Anthropol Q
	Cochrane Database Syst Rev
revisão sistemática	Revista Panamericana de Salud Publica
	Rev Saude Publica
	ScientificWorldJournal
	J Crohns Colitis
	Nat Rev Rheumatol
we are going	Autoimmun Rev
	Nat Rev Rheumatol
	Rheumatology (Oxford)
	Nat Rev Rheumatol
ive homogeneous recombinant human granulocyte and macrophage colony	Int J Biol Macromol
eorgetown Public Hospital Corporation: a retrospective chart review	BMC infectious diseases
neumatoid arthritis: 72-week data from a randomized Phase 3 trial	Rheumatology (Oxford)
	Rev. panam. salud pública
tient infected with human immunodeficiency virus	Revista do Instituto de Medicina Tropical de Sao Paulo
tions from Rio de Janeiro, Brazil	Memorias do Instituto Oswaldo Cruz
randomized, open-label, two-period crossover study in healthy Brazilian	Clinical therapeutics
ents with type 1 diabetes: systematic review and meta-analysis	Ther Adv Endocrinol Metab
gical approach]	Rev Assoc Med Bras (1992)
gy for Cancer Treatment	Curr Med Chem

Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	<b>Author</b>	<b>Year</b>	<b>Title</b>
477	Smolen, J. S., S. B. Cohen, H. P. Tony, M. Scheinberg, A. Kivitz, A. Balanescu, J. Gomez-Reino, L. Cen, J. Poetzl, T. Shisha and D. Kollins	2021	Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis
478	Smolen, J. S., S. B. Cohen, H. P. Tony, M. Scheinberg, A. Kivitz, A. Balanescu, J. Gomez-Reino, L. Cen, P. Zhu and T. Shisha	2017	A randomised, double-blind trial to demonstrate bioequivalence of GP2013 in active rheumatoid arthritis
479	Smolen, J. S., R. Landewé, J. Bijlsma, G. Burmester, K. Chatzidionysiou, M. Dougados, J. Nam, S. Ramiro, M. Voshaar, R. van Vollenhoven, D. Aletaha, M. Aringer, M. Boers, C. D. Buckley, F. Buttgerit, V. Bykerk, M. Cardiel, B. Combe, M. Cutolo, Y. van Eijk-Hustings, P. Emery, A. Finckh, C. Gabay, J. Gomez-Reino, L. Gossec, J. E. Gottenberg, J. M. W. Hazes, T. Huizinga, M. Jani, D. Karateev, M. Kouloumas, T. Kvien, Z. Li, X. Mariette, I. McInnes, E. Mysler, P. Nash, K. Pavelka, G. Poór, C. Richez, P. van Riel, A. Rubbert-Roth, K. Saag, J. da Silva, T. Stamm, T. Takeuchi, R. Westhovens, M. de Wit and D. van der Heijde	2017	EULAR recommendations for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: update
480	Smolen, J. S., R. B. M. Landewé, J. W. J. Bijlsma, G. R. Burmester, M. Dougados, A. Kerschbaumer, I. B. McInnes, A. Sepriano, R. F. van Vollenhoven, M. de Wit, D. Aletaha, M. Aringer, J. Askling, A. Balsa, M. Boers, A. A. den Broeder, M. H. Buch, F. Buttgerit, R. Caporali, M. H. Cardiel, D. De Cock, C. Codreanu, M. Cutolo, C. J. Edwards, Y. van Eijk-Hustings, P. Emery, A. Finckh, L. Gossec, J. E. Gottenberg, M. L. Hetland, T. W. J. Huizinga, M. Koloumas, Z. Li, X. Mariette, U. Müller-Ladner, E. F. Mysler, J. A. P. da Silva, G. Poór, J. E. Pope, A. Rubbert-Roth, A. Ruysen-Witrand, K. G. Saag, A. Strangfeld, T. Takeuchi, M. Voshaar, R. Westhovens and D. van der Heijde	2020	EULAR recommendations for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: update
481	Soares, J. C. S., I. D. L. Cavalcanti and J. L. A. Vasconcelos	2021	Can biosimilar products be interchangeable? Pharmaceutical perspective in Brazil
482	Soares, K. C., M. V. Moraes, G. M. Gelfuso and T. Gratieri	2015	[Bioequivalence of dermatological topical medicines:the Brazilian scenario]
483	Soares, K. C., G. M. Santos, G. M. Gelfuso and T. Gratieri	2015	An Update of the Brazilian Regulatory Bioequivalence Recommendations
484	Soares, K. C. C., C. Chiann and S. Storpirtis	2022	Assessment of the impact of partial area under the curve in a bioavailability study
485	Soares, K. C. C., W. C. de Souza, S. Texeira L. de, M. S. S. da Cunha-Filho, G. M. Gelfuso and T. Gratieri	2018	Comparison of Clobetasol Propionate Generics Using Simplified In vitro Bioequivalence
486	Soto, J., L. Valda-Rodriguez, J. Toledo, L. Vera-Navarro, M. Luz, H. Monasterios-Torrico, J. Vega and J. Berman	2004	Comparison of generic to branded pentavalent antimony for treatment of malaria
487	Soubeyran, P., C. A. Bellera, F. Gregoire, J. Blanc, J. Ceccaldi, C. Blanc-Bisson, C. Mertens, S. Mathoulin-Pelissier, M. Fonck and M. Rainfray	2008	Validation of a screening test for elderly patients in oncology
488	Sousa, C. V., J. M. Mesquita and J. E. Lara	2013	[Analysis of the decision to buy medicine in light of the existence of generic drugs]
489	Souza, C. M. A., J. Paranhos and L. Hasenclever	2021	Comparison between maximum consumer prices for medicines and prices in Brazil
490	Stankievich, E., A. Malanca, I. Foradori, S. Ivalo and M. Losso	2018	Utility of Mobile Communication Devices as a Tool to Improve Adherence to Medication in Argentina
491	Steinberg, J., Y. D. Fragoso, J. C. Duran Quiroz, J. R. García, C. Guerra, V. Rodriguez, C. Carcamo Rodriguez, E. Ciampi, E. Correa-Díaz, M. Macías, N. Navarro, D. Vizcarra, C. Oehninger Gatti, G. Orozco and A. Carrá	2019	Practical Issues Concerning the Approval and Use of Biosimilar Drugs for Rheumatoid Arthritis
492	Steinbrook, R.	2007	Thailand and the compulsory licensing of efavirenz
493	Stillitano, I. G., M. G. Lima, M. P. Ribeiro, J. Cabral and C. T. Brandt	2005	[Economic impact of eyedrop cost in glaucoma treatment]
494	Strand, V., A. Balsa, J. Al-Saleh, L. Barile-Fabris, T. Horiuchi, T. Takeuchi, S. Lula, C. Hawes, B. Kola and L. Marshall	2017	Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
495	Strusberg, I., E. Mysler, G. Citera, D. Siri, M. de Los Angeles Correa, M. A. Lazaro, R. Pardo Hidalgo, A. Spindler, P. Tate, H. Venarotti, J. Velasco Zamora, E. Klimovsky, A. Federico, E. Scheines, E. Gonzalez, L. Cordeiro and N. Lago	2021	Efficacy, Safety, and Immunogenicity of Biosimilar Etanercept (Enercepta) With Rheumatoid Arthritis: A Randomized, Multicenter, Evaluator-Blinded Trial
496	Suh, C. H., D. H. Yoo, A. Berrocal Kasay, E. Chalouhi El-Khoury, F. F. Cons Molina, P. Shesternya, P. Miranda, F. G. Medina-Rodriguez, P. Wiland, S. Jeka, J. Chavez-Corrales, T. Linde, P. Hrycaj, M. Abello-Banfi, I. Hospodarsky, J. Jaworski, M. Piotrowski, M. Brzosko, M. Krogulec, S. Shevchuk, A. Calvo, D. Anderson, W. Park, S. C. Shim, S. J. Lee and S. Y. Lee	2019	Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in a Phase III Trial
497	Tängdén, T., C. Pulcini, H. Aagaard, M. Balasegaram, G. L. Hara, D. Nathwani, M. Sharland, U. Theuretzbacher and O. Cars	2018	Unavailability of old antibiotics threatens effective treatment for common infections

	Journal
Arthritis: 52-week results from the randomized controlled ASSIST-RA trial	Rheumatology (Oxford)
3 and reference rituximab combined with methotrexate in patients with active	Ann Rheum Dis
h synthetic and biological disease-modifying antirheumatic drugs: 2016	Ann Rheum Dis
h synthetic and biological disease-modifying antirheumatic drugs: 2019	Ann Rheum Dis
n the implementation of biosimilars in oncology	J Oncol Pharm Pract
o and the challenges for health surveillance]	Cien Saude Colet
for Approval of Generic Topical Dermatological Drug Products	Aaps j
y/bioequivalence study on generic prolonged-release formulations	Eur J Pharm Sci
Bioequivalence Method for Topical Drug Products	Curr Drug Deliv
ew world cutaneous leishmaniasis	Am J Trop Med Hyg
	ASCO Meeting Abstracts
ic products: a study in the city of Belo Horizonte, Brazil]	Cien Saude Colet
practiced on the internet in Brazil: misalignments and regulatory distortions	Cien Saude Colet
e to Antiretroviral Treatment in HIV-infected Children and Young Adults in	The Pediatric infectious disease journal
the Treatment of Multiple Sclerosis in Latin America	Neurol Ther
	N Engl J Med
	Arq Bras Oftalmol
natic Review	BioDrugs
n) Versus Its Original Form in Combination With Methotrexate in Patients d, Noninferiority Study	J Clin Rheumatol
rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized	BioDrugs
bacterial infections	Lancet Infect Dis

Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	Author	Year	Title
498	Tattevin, P., A. C. Crémieux, C. Rabaud and R. Gauzit	2014	Efficacy and quality of antibacterial generic products approved for human
499	Taylor, P. W., I. Arnet, A. Fischer and I. N. Simpson	2010	Pharmaceutical quality of nine generic orlistat products compared with Xe
500	Tchen, N., P. Soubeyran, H. Eghbali, J. Ceccaldi, L. Cany, J. C. Balzon, P. Remuzon, M. Malet, F. Bonichon, V. Picot, A. Monnerau, B. Hoerni and Lymphomes Sud-Ouest	2002	Quality of life in patients with aggressive non-Hodgkin's lymphoma. Valid symptom checklist in older patients
501	Teixeira, F. V., P. G. Kotze and A. O. Damião	2016	ANVISA APPROVES THE FIRST BIOSIMILAR MONOCLONAL ANT
502	Teixeira, M. T., L. C. L. Sá-Barreto, T. Gratieri, G. M. Gelfuso, I. C. R. Silva and M. S. S. Cunha-Filho	2017	Key Technical Aspects Influencing the Accuracy of Tablet Subdivision
503	Tejada, R. A., T. Malagón and E. L. Franco	2022	Cost-effectiveness of human papillomavirus vaccination in girls living in L
504	Teran, E., H. Gomez, D. Hannois, M. Lema, W. Mantilla, M. Rico-Restrepo, E. McElwee, N. Castro Sanchez, N. Valdivieso and M. A. Espinoza	2022	Streamlining breast cancer and colorectal cancer biosimilar regulations to
505	Tierrablanca, L. E., J. Ochalek, D. Ford, A. Babiker, D. Gibb, K. Butler, A. Turkova, S. Griffin and P. Revill	2018	Economic evaluation of weekends-off antiretroviral therapy for young peo
506	Toffoletto, O., J. Afione, J. E. Thiemann, S. S. Khandave, S. Patel and D. G. Rodrigues	2016	Comparative pharmacokinetic and pharmacodynamic evaluation between a
507	Torres-Obreque, K. M., G. P. Meneguetti, J. J. Muso-Cachumba, V. A. Feitosa, Jhpm Santos, S. P. M. Ventura and C. O. Rangel-Yagui	2022	Building better biobetters: From fundamentals to industrial application
508	Tostes, M. A., M. Chalub and N. J. Botega	2004	The quality of life of HIV-infected women is associated with psychiatric m
509	Trapani, D., C. G. Lengyel, B. S. Habeeb, S. C. Altuna, A. Petrillo, K. El Bairi, S. Hussain, S. A. Mazher, E. M. Elfaham, G. Curigliano and S. Z. Khan	2021	The global landscape of availability, accessibility and affordability of essen breast cancer: The ONCOLLEGE-001 survey
510	Triplitt, C., D. Hinnen and V. Valentine	2017	How Similar Are Biosimilars? What Do Clinicians Need to Know About B
511	Trukhin, D., E. Poddubskaya, Z. Andric, T. Makharadze, R. S. Bellala, C. Charoentum, E. P. Yañez Ruiz, A. Fulop, I. A. Hyder Ali, K. Syrigos, N. Katgi, Y. A. Lopez Chukun, I. Romyana, J. Reyes-Igama, R. C. Costamilan, A. Del Campo García, A. Florez, A. Paravisini and S. Millan	2021	Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) A Randomized, Double-Blind, Phase III Study (STELLA)
512	Tsang, S. F., S. Pandya, K. Barakov, J. Keutzer, G. Lewis, L. Ross and S. Freisens	2022	Use of Identical INN "Imiglucerase" for Different Drug Products: Impact a
513	Tsuruta, L. R., M. Lopes dos Santos and A. M. Moro	2015	Biosimilars advancements: Moving on to the future
514	Tzanno-Martins, C., B. M. Biavo, O. Ferreira-Filho, E. Ribeiro-Junior, M. V. João-Luiz, S. Degaspari, C. Scavone and E. Kawamoto	2014	Clinical efficacy, safety and anti-inflammatory activity of two sevelamer ta
515	Urbano, P. C., V. T. Soccol and V. F. Azevedo	2014	Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic cri
516	Valeria, Sandoval-Santacruz and Real-Pérez Grether	2020	Oportunidad de crecimiento de la Educación Superior Virtual Pos Covid-1
517	Vanz, A. L., G. Renard, M. S. Palma, J. M. Chies, S. L. Dalmora, L. A. Basso and D. S. Santos	2008	Human granulocyte colony stimulating factor (hG-CSF): cloning, overexp
518	Varallo, F. R., M. Forgerini, M. T. Herdeiro and P. de Carvalho Mastroianni	2019	Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities
519	Vargas, J. I., J. P. Arab, H. Monrroy, P. Labbé, V. Sarmiento, F. Fuster, F. Barrera, C. Benitez, M. Arrese, F. Fuster and A. Soza	2017	[Direct antivirals for the treatment of chronic hepatitis C virus infection. E
520	Velasco-Velázquez, M. A., N. Salinas-Jazmín, E. Hisaki-Itaya, L. Cobos-Puc, W. Xolalpa, G. González, A. Tenorio-Calvo, N. Piña-Lara, L. C. Juárez-Bayardo, L. F. Flores-Ortiz, E. Medina-Rivero, N. O. Pérez and S. M. Pérez-Tapia	2017	Extensive preclinical evaluation of an infliximab biosimilar candidate
521	Vencio, S., R. Caiado-Vencio, L. F. Caixeta, M. Masierek, W. Mlynarski, J. Drzewoski and J. M. Gregory	2022	A randomized pharmacokinetic and pharmacodynamic trial of two regular availability of biosimilar insulin may improve access to this medication
522	Verschraegen, C., Z. Andric, F. Moiseenko, T. Makharadze, S. Shevnya, A. Oleksienko, E. Yañez Ruiz, S. Kim, K. Ahn, T. Park, S. Park, H. Ju and Y. Ohe	2022	Candidate Bevacizumab Biosimilar CT-P16 versus European Union Referer Lung Cancer: A Randomized Controlled Trial
523	Vesga, O., M. Agudelo, B. E. Salazar, C. A. Rodriguez and A. F. Zuluaga	2010	Generic vancomycin products fail in vivo despite being pharmaceutical eq
524	Vial, J., M. Cohen, P. Sassiati and D. Thiébaud	2008	Pharmaceutical quality of docetaxel generics versus originator drug produ
525	Vicencio Acevedo, D., A. Alfaro Valle and J. L. Martínez Toledo	1995	[Characteristics of drug acquisition in Morelia (Michoacán), Mexico]

	Journal
use: a systematic review	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
anical(r)	Obes Facts
ation of the medical outcomes study short form 20 and the Rotterdam	Critical reviews in oncology/hematology
IBODY BASED ON COMPARABILITY IN BRAZIL	Arq Gastroenterol
	AAPS PharmSciTech
Latin American countries: A systematic review and meta-analysis	Vaccine
improve treatment access in Latin America: an expert panel perspective	Lancet Oncol
ple in 11 countries	Medicine (Baltimore)
a new biosimilar and reference recombinant human growth hormone	Growth Horm IGF Res
	Drug Discov Today
orbidity	AIDS care
tial diagnostics and therapeutics for the management of HER2-positive	J Cancer Policy
Biosimilar and Follow-On Insulins?	Clin Diabetes
versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer:	BioDrugs
Analysis of Adverse Events in a Proprietary Global Safety Database	Drug Saf
	Biotechnol Prog
ablet forms in patients on low-flux hemodialysis	Int J Immunopathol Pharmacol
teria for biosimilar TNF-alpha antagonists	Biologics
9	
ression, purification and characterization	Microb Cell Fact
to Improve Risk Communication	Clin Ther
experience in 106 patients]	Rev Med Chil
	Eur J Pharm Sci
human insulins demonstrates bioequivalence in type 1 diabetes and	Diabetes Obes Metab
ence Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell	BioDrugs
uivalents of the innovator	Antimicrob Agents Chemother
ct: a comparative analysis	Curr Med Res Opin
	Boletín de la Oficina Sanitaria Panamericana. Pan American Sanitary Bureau



## Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	<b>Author</b>	<b>Year</b>	<b>Title</b>
526	Videla, C. and C. Godoy	2007	Converting to a generic formulation of mycophenolate mofetil in stable kidney disease
527	Vigani, A. G., E. S. Gonçalves, M. H. Pavan, F. Genari, R. Tozzo, M. S. Lazarini, V. Fais, A. Feltrin, N. S. Gonçalves and F. L. Gonçalves, Jr.	2012	Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon in patients with chronic hepatitis C
528	Vilanova, E., B. F. Glauser, S. M. Oliveira, A. M. Tovar and P. A. Mourão	2016	Update on Brazilian biosimilar enoxaparins
529	Vilchez-Román, C., S. Sanguinetti and E. Mezones-Holguin	2019	Comment on: "The Impact of Patent Expiry on Drug Prices: A Systematic Review of the Literature"
530	von Minckwitz, G., M. Colleoni, H. C. Kolberg, S. Morales, P. Santi, Z. Tomasevic, N. Zhang and V. Hanes	2018	Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive advanced breast cancer: a phase 3, randomised, double-blind, phase 3 trial
531	Wadhwa, M., H. N. Kang, H. Hamel and T. Jivapaisampong	2018	WHO informal consultation on development of guidelines on procedures and standards for biosimilars, Seoul, Republic of Korea, 27-28 April 2017
532	Wadhwa, M., H. N. Kang, R. Thorpe, I. Knezevic, P. Aprea, M. C. Bielsky, N. Ekman, H. K. Heim, J. Joung, P. Kurki, E. Lacana, C. Njue, E. Nkansah, M. Savkina, R. Thorpe, T. Yamaguchi, M. Wadhwa, J. Wang, M. Weise and E. Wolff-Holz	2022	WHO informal consultation on revision of guidelines on evaluation of similarity of biosimilars
533	Wang, T., S. W. Hoag, M. L. Eng, J. Polli and N. S. Pandit	2015	Quality of antiretroviral and opportunistic infection medications dispensed in community pharmacies in the United States
534	Ward, L. S.	2011	[Levothyroxine and the problem of interchangeability of drugs with narrow therapeutic index]
535	Wattel, E., M. Mariotti, F. Agis, E. Gordien, O. Prou, A. M. Courouze, P. Rouger, S. Wain-Hobson, I. S. Chen and J. J. Lefrère	1992	Human T lymphotropic virus (HTLV) type I and II DNA amplification in patients with hairy-cell leukemia
536	Weir, M. R., P. E. Pergola, R. Agarwal, J. C. Fink, N. P. Kopyt, A. K. Singh, J. Kumar, S. Schmitt, G. Schaffar, A. Rudy, J. P. McKay and R. Kanceva	2017	A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) and Epoetin Alfa in Patients with End-Stage Renal Disease
537	Westhovens, R., P. Wiland, M. Zawadzki, D. Ivanova, A. B. Kasay, E. C. El-Khoury, É Balázs, S. Shevchuk, L. Eliseeva, M. Stanislavchuk, R. Yatsyshyn, P. Hrycaj, J. Jaworski, V. Zhdan, J. Trefler, P. Shesternya, S. J. Lee, S. H. Kim, J. H. Suh, S. G. Lee, N. R. Han and D. H. Yoo	2021	Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous rituximab in patients with rheumatoid arthritis
538	Wiland, P., S. Jeka, E. Dokoupilová, J. Brandt-Jürgens, J. M. Miranda Limón, M. Cantalejo Moreira, R. V. Cabello, J. Jauch-Lembach, A. Thakur, H. Haliduola, I. Brueckmann and N. B. Gaylis	2020	Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Ankylosing Spondylitis: Results From the Phase III, Randomized, Double-Blind ADMYRA Study
539	Ximenez, J. P., V. L. Lanchote, M. A. Bello, F. H. S. Iocken, R. C. M. Obadia, V. P. de Sousa and G. Suarez-Kurtz	2020	Post-marketing assessment of generic tamoxifen in Brazilian breast cancer patients
540	Yang, Y. T., S. Nagai, B. K. Chen, Z. P. Qureshi, A. A. Lebby, S. Kessler, P. Georgantopoulos, D. W. Raisch, O. Sartor, T. Hermanson, R. C. Kane, W. J. Hrushesky, J. J. Riente, L. B. Norris, L. R. Bobolts, J. O. Armitage and C. L. Bennett	2016	Generic oncology drugs: are they all safe?
541	Yoo, D. H., N. Prodanovic, J. Jaworski, P. Miranda, E. Ramitterre, A. Lanzon, A. Baranauskaitė, P. Wiland, C. Abud-Mendoza, B. Oparanov, S. Smiyan, H. Kim, S. J. Lee, S. Kim and W. Park	2017	Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: 54-week results from the PLANETRA extension study
542	Yoo, D. H., A. Racewicz, J. Brzezicki, R. Yatsyshyn, E. T. Arteaga, A. Baranauskaitė, C. Abud-Mendoza, S. Navarra, V. Kadinov, I. G. Sariego, S. S. Hong, S. Y. Lee and W. Park	2016	A phase III randomized study to evaluate the efficacy and safety of CT-P13 in patients with rheumatoid arthritis: 54-week results from the PLANETRA study
543	Yoo, D. H., C. H. Suh, S. C. Shim, S. Jeka, F. F. C. Molina, P. Hrycaj, P. Wiland, E. Y. Lee, F. G. Medina-Rodriguez, P. Shesternya, S. Radominski, M. Stanislav, V. Kovalenko, D. H. Sheen, L. Myasoutova, M. J. Lim, J. Y. Choe, S. J. Lee, S. Y. Lee, S. H. Kim and W. Park	2017	Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar (CT-P13) in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial
544	Zarocostas, J.	2009	Brazil and India clash with EU over seizure of generic drugs
545	Zarocostas, J.	2010	Brazil and India file complaint against EU over seizure of generic drugs
546	Zenati, N., J. L. Bosson, S. Blaise and P. Carpentier	2017	[Health related quality of life in chronic venous disease: Systematic literature review]
547	Zhao, S., L. Chadwick, E. Mysler and R. J. Moots	2018	Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
548	Zhao, S., E. Mysler and R. J. Moots	2018	Etanercept for the treatment of rheumatoid arthritis
549	Zuluaga, A. F., M. Agudelo, J. J. Cardeño, C. A. Rodriguez and O. Vesga	2010	Determination of therapeutic equivalence of generic products of gentamicin
550	Zuluaga, A. F., C. A. Rodriguez, M. Agudelo and O. Vesga	2014	About the validation of animal models to study the pharmacodynamics of drugs
551	Allenet, B. and H. Barry	2003	Opinion and behaviour of pharmacists towards the substitution of branded drugs
552	Araújo, L. U., K. T. Albuquerque, K. C. Kato, G. S. Silveira, N. R. Maciel, P. A. Spósito, N. M. Barcellos, J. d. Souza, M. Bueno and S. Storpirtis	2010	[Generic drugs in Brazil: historical overview and legislation]
553	Arcaro, R., C. R. P. da Veiga, W. V. da Silva and C. Pereira da Veiga	2021	Attitude and Purchase Intention to Generic Drugs

	Journal
kidney transplant recipients: 1 year of drug surveillance and outcome	Transplant Proc
and interferon for chronic hepatitis C genotypes 2 or 3	Braz J Infect Dis
	Expert Rev Hematol
"Literature Review"	Appl Health Econ Health Policy
women with HER2-positive early breast cancer (LILAC study): a randomised,	Lancet Oncol
and data requirements for changes to approved biotherapeutic products,	Biologicals
ilar biotherapeutic products, virtual meeting, 30 June - 2 July 2021	Biologicals
from developing countries and Internet pharmacies	J Clin Pharm Ther
w therapeutic index]	Arq Bras Endocrinol Metabol
HTLV-I/II-seropositive blood donors of the French West Indies	The Journal of infectious diseases
ed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease	Am J Nephrol
CT-P13 in rheumatoid arthritis: a randomized phase I/III trial	Rheumatology (Oxford)
ctive Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity	BioDrugs
patients	Basic Clin Pharmacol Toxicol
	Lancet Oncol
umatoid arthritis: comparison between switching from reference infliximab to	Ann Rheum Dis
3 compared with reference infliximab in patients with active rheumatoid	Arthritis Res Ther
umab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with ntrolled Trial	BioDrugs
	Bmj
	Bmj
ure review]	Journal de medecine vasculaire
ritis	Curr Rheumatol Rep
	Immunotherapy
n in the neutropenic mouse thigh infection model	PLoS One
generic antimicrobials	Clin Infect Dis
drugs by generic drugs: survey of 1,000 French community pharmacists	Pharmacy world & science : PWS
	Rev Panam Salud Publica
	Int J Environ Res Public Health

## Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	<b>Author</b>	<b>Year</b>	<b>Title</b>
554	Ascef, B. O., Rgld Silva, H. A. Oliveira Júnior and P. C. Soárez	2019	Interchangeability and substitution of biosimilars: is health technology ass
555	Azevedo, V. F., A. Babini, C. V. Caballero-Urbe, G. Castañeda-Hernández, C. Borlenghi and H. E. Jones	2019	Practical Guidance on Biosimilars, With a Focus on Latin America: What I
556	Azevedo, V. F., S. Meirelles Ede, A. Kochen Jde, A. C. Medeiros, S. J. Mízputen, F. V. Teixeira, A. O. Damião, P. G. Kotze, R. Romiti, M. Arnone, R. F. Magalhães, C. P. Maia and A. V. de Carvalho	2015	Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology and Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease: proteins used in the treatment of autoimmune diseases
557	Barata-Silva, Cristiane, Rachel Ann Hauser-Davis, André Luiz Oliveira da Silva and Josino Costa Moreira	2017	Challenges to the drug quality control in Brazil
558	Bennett, C. L., B. Chen, T. Hermanson, M. D. Wyatt, R. M. Schulz, P. Georgantopoulos, S. Kessler, D. W. Raisch, Z. P. Qureshi, Z. K. Lu, B. L. Love, V. Noxon, L. Bobolts, M. Armitage, J. Bian, P. Ray, R. J. Ablin, W. J. Hrushesky, I. C. Macdougall, O. Sartor and J. O. Armitage	2014	Regulatory and clinical considerations for biosimilar oncology drugs
559	Bertoldi, A. D., A. J. Barros and P. C. Hallal	2005	Generic drugs in Brazil: known by many, used by few
560	Cazap, E., I. Jacobs, A. McBride, R. Popovian and K. Sikora	2018	Global Acceptance of Biosimilars: Importance of Regulatory Consistency,
561	da Fonseca, E. M. and K. C. Shadlen	2017	Promoting and regulating generic medicines: Brazil in comparative perspe
562	Davit, B., A. C. Braddy, D. P. Conner and L. X. Yu	2013	International guidelines for bioequivalence of systemically available orally
563	Esteban, E., R. H. Bustos, J. C. García and E. Jáuregui	2019	Biosimilars: An Approach to some Current Worldwide Regulation Framew
564	García Arieta, A., C. Simon, G. M. Lima Santos, I. O. Calderón Lojero, Z. Rodríguez Martínez, C. Rodrigues, S. A. Park, J. M. Kim, R. Kuribayashi, Y. Okada, A. Nolting, C. Pfäffli, W. Y. Hung, C. Crane, A. C. Braddy, J. Van Oudtshoorn, D. Gutierrez Triana and M. Clarke	2019	A Survey of the Regulatory Requirements for the Acceptance of Foreign Countries: International Generic Drug Regulators Programme
565	García, R. and D. V. Araujo	2016	The Regulation of Biosimilars in Latin America
566	González-Ramírez, R. and G. Castañeda-Hernández	2019	The challenges of developing and commercializing biosimilars in Latin Am
567	Hassali, M. A., A. A. Shafie, S. Jamshed, M. I. Ibrahim and A. Awaisu	2009	Consumers' views on generic medicines: a review of the literature
568	Helguera, G.	2019	[Background of regulations for similar biological medications in Argentina]
569	Homedes, N. and A. Ugalde	2005	Multisource drug policies in Latin America: survey of 10 countries
570	Homedes, N., A. Ugalde and J. R. Forns	2005	The World Bank, pharmaceutical policies, and health reforms in Latin Am
571	Ibarra-Cabrera, R., S. C. Mena-Pérez, A. Bondani-Guasti and R. García-Arrazola	2013	Review on the worldwide regulatory framework for biosimilars focusing o
572	Kang, H. N., R. Thorpe and I. Knezevic	2020	The regulatory landscape of biosimilars: WHO efforts and progress made i
573	Kang, H. N., R. Thorpe, I. Knezevic, M. Casas Levano, M. B. Chilufya, P. Chirachanakul, H. M. Chua, D. Dalili, F. Foo, K. Gao, S. Hababbeh, H. Hamel, G. H. Kim, V. Perez Rodriguez, D. E. Putri, J. Rodgers, M. Savkina, O. Semeniuk, S. Srivastava, J. Tavares Neto, M. Wadhwa and T. Yamaguchi	2021	Regulatory challenges with biosimilars: an update from 20 countries
574	Kaplan, W. A., J. Cárdenas, C. Mansilla, T. Tobar and V. J. Wirtz	2019	The implementation of the bioequivalence certification policy in Chile: An
575	Kaplan, W. A., V. J. Wirtz and P. Stephens	2013	The market dynamics of generic medicines in the private sector of 19 low
576	Kay, J.	2011	Biosimilars: a regulatory perspective from America
577	Kos, I. A., V. F. Azevedo, D. E. Neto and S. C. Kowalski	2018	The biosimilars journey: current status and ongoing challenges
578	Lee, S. L., B. Saluja, A. García-Arieta, G. M. Santos, Y. Li, S. Lu, S. Hou, J. Rebello, A. Vaidya, J. Gogtay, S. Purandare and S. Lyapustina	2015	Regulatory Considerations for Approval of Generic Inhalation Drug Produ
579	Levy, R.	1999	[Utilization of interchangeable generic drugs in Mexico]
580	Lietzan, E.	2018	How Colombia's biosimilar regulation departs from international norms
581	Lizarraga, A. and E. Mysler	2019	Similar and mimics: Latin America biosimilar regulations
582	López Silva, C.	2012	[Mexico recovers leadership on regulation of biosimilar biotech drugs]
583	Loyola, M. A.	2008	[Drugs, health policy and AIDS: changes in a dependent policy]
584	Luo, J., M. A. Oliveira, M. B. Ramos, A. Maia and C. G. Osorio-de-Castro	2014	Antiretroviral drug expenditure, pricing and judicial demand: an analysis o
585	Machado-Alba, J. E., V. Alzate-Carvajal and C. E. Jimenez-Canizales	2015	[Trends in the consumption of anxiolytic and hypnotic drugs in a Colombi
586	Madden, J. M., E. Meza, M. Ewen, R. O. Laing, P. Stephens and D. Ross-Degnan	2010	Measuring medicine prices in Peru: validation of key aspects of WHO/HA

	Journal
essment (HTA) a tool for decision-making?	Cad Saude Publica
Do Rheumatologists Need to Know?	J Clin Rheumatol
neumatology, Brazilian Society of Dermatology, Brazilian Federation of ease--Focus on clinical evaluation of monoclonal antibodies and fusion	Autoimmun Rev
	Cad. saúde colet., (Rio J.)
	Lancet Oncol
	Cad Saude Publica
Education, and Trust	Oncologist
ective	Rev Panam Salud Publica
y administered generic drug products: a survey of similarities and differences	Aaps j
orks	Curr Clin Pharmacol
Comparator Products by Participating Regulators and Organizations of the	J Pharm Pharm Sci
	Curr Rheumatol Rep
merica	Pharm Pat Anal
	Int J Pharm Pract
	Medicina (B Aires)
	Bull World Health Organ
merica	Int J Health Serv
on the Mexican case as an emerging market in Latin America	Biotechnol Adv
from 2009 to 2019	Biologicals
	Ann N Y Acad Sci
analysis of market authorization data	PLoS One
and middle income countries between 2001 and 2011: a descriptive time	PLoS One
	Arthritis Res Ther
	Drugs Context
cts in the US, EU, Brazil, China, and India	Aaps j
	Salud Publica Mex
	Rev Panam Salud Publica
	Int J Rheum Dis
	Gac Med Mex
	Cien Saude Colet
f federal procurement data in Brazil from 2004-2011	BMC Public Health
an population]	Rev Colomb Psiquiatr
I survey methodology	Rev Panam Salud Publica

Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	<b>Author</b>	<b>Year</b>	<b>Title</b>
587	Marcelín-Jiménez, G., A. P. Angeles-Moreno, L. Contreras-Zavala, A. García-González and E. Ramírez-San Juan	2012	Comparison of fasting bioavailability among 100-mg commercial, 100-mg Mexican volunteers: a single-dose, 3-period, crossover study
588	Mendis, S., K. Fukino, A. Cameron, R. Laing, A. Filipe, O. Khatib, J. Leowski and M. Ewen	2007	The availability and affordability of selected essential medicines for chronic
589	Miranda, E. S., B. Pinto Cdu, A. L. dos Reis, I. C. Emmerick, M. R. Campos, V. L. Luiza and C. G. Osorio-de-Castro	2009	[Availability of generic drugs in the public sector and prices in the private
590	Moïse, P. and E. Docteur	2008	[Policies concerning pharmaceutical prices and reimbursement in Mexico,
591	Molina-Salazar, R. E. and J. E. Rivas-Vilchis	1998	[Overpricing and affordability of drugs: the case of essential drugs in Mex
592	Mosegui, G. B. G., F. Antónanzas, C. M. de Mello Vianna and P. Rojas	2021	Drug prices in Latin American countries: the case of rheumatoid arthritis E
593	Mysler, E.	2015	Biosimilars: clinical interpretation and implications for drug development
594	Mysler, E., C. Pineda, T. Horiuchi, E. Singh, E. Mahgoub, J. Coindreau and I. Jacobs	2016	Clinical and regulatory perspectives on biosimilar therapies and intended c
595	Mysler, E. and M. Scheinberg	2012	Biosimilars in rheumatology: a view from Latin America
596	Nunn, A., S. Dickman, N. Natrass, A. Cornwall and S. Gruskin	2012	The impacts of AIDS movements on the policy responses to HIV/AIDS in
597	Nunn, A., E. D. Fonseca and S. Gruskin	2009	Changing global essential medicines norms to improve access to AIDS trea
598	Ordóñez, K., M. M. Feinstein, S. Reyes, C. Hernández-Gómez, C. Pallares and M. V. Villegas	2019	Clinical and economic impact of generic versus brand name meropenem u
599	Orellana, C.	2001	Generic drugs to increase access to chemotherapy in Chile
600	Orsi, F., C. D'Almeida, L. Hasenclever, M. Camara, P. Tigre and B. Coriat	2007	TRIPS post-2005 and access to new antiretroviral treatments in southern c
601	Paranhos, J., E. Mercadante and L. Hasenclever	2020	[The cost to the Brazilian Unified National Health System of the extension
602	Paumgarten, F. J. R. and Acax Oliveira	2017	Nonbioequivalent prescription drug interchangeability, concerns on patient
603	Perez-Chauca, E. and H. Gomes Ferraz	2021	[Interchangeability of drugs in Peru: current outlook and future perspectiv
604	Petherick, A.	2011	Chile plans new agency to boost pharma oversight
605	Pineda, C., C. V. Caballero-Urbe, M. G. de Oliveira, P. S. Lipszyc, J. J. Lopez, M. M. Mataos Moreira and V. F. Azevedo	2015	Recommendations on how to ensure the safety and effectiveness of biosim
606	Pinheiro Edos, S., K. Brüning, M. F. Macedo and A. C. Siani	2014	Production of antiretroviral drugs in middle- and low-income countries
607	Pinto Cdu, B., E. S. Miranda, I. C. Emmerick, R. Costa Ndo and C. G. Castro	2010	Medicine prices and availability in the Brazilian Popular Pharmacy Progra
608	Quental, C., J. C. de Abreu, J. V. Bomtempo and C. A. Gadelha	2008	[Generic drugs in Brazil: impacts of public policies upon the national indu
609	Rahalkar, H., A. Sheppard, C. A. Lopez-Morales, L. Lobo and S. Salek	2021	Challenges Faced by the Biopharmaceutical Industry in the Development a Countries: An Exploratory Study
610	Rahalkar, H., A. Sheppard and S. Salek	2021	Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks
611	Rahalkar, H., A. Sheppard, G. M. L. Santos, C. Dasgupta, S. M. Perez-Tapia, C. A. Lopez-Morales and S. Salek	2021	Current Regulatory Requirements for Biosimilars in Six Member Countrie
612	Rathore, A. S. and A. Bhargava	2021	Regulatory considerations in biosimilars: Latin America region
613	Redigueri, C. F., R. Cristofolletti, K. C. Soares and J. Tavares-Neto	2014	Similarities and differences of international guidelines for bioequivalence:
614	Reséndez, C., F. Garrido and O. Gómez-Dantés	2000	[Availability of essential medications at primary level units of the Health D
615	Rosenberg, S. T.	2014	Asserting the primacy of health over patent rights: a comparative study of Brazil
616	Rosina, M. S. and L. Shaver	2012	Why are generic drugs being held up in transit? Intellectual property rights
617	Ruiz, R., K. Strasser-Weippl, D. Touya, C. Herrero Vincent, A. Hernandez-Blanquissett, J. St Louis, A. Bukowski and P. E. Goss	2017	Improving access to high-cost cancer drugs in Latin America: Much to be
618	Scheinberg, M., C. Pineda, G. Castañeda-Hernández, J. J. Zarbá, A. Damião, L. H. Arantes, Jr. and I. Jacobs	2018	Biosimilars in oncology and inflammatory diseases: current and future con
619	Scheinberg, M. A., P. A. O. Felix, I. A. Kos, M. A. Andrade and V. F. Azevedo	2018	Partnership for productive development of biosimilar products: perspectiv
620	Shaffer, E. R. and J. E. Brenner	2009	A trade agreement's impact on access to generic drugs
621	Stirner, B. and H. Thangaraj	2013	Learning from practice: compulsory licensing cases and access to medicin
622	Stojanova, J., M. Lutz, G. Lazcano and M. Arancibia	2020	Main concepts on bioequivalence and biosimilarity in the Chilean legislati

	Journal
generic, and 50-mg chewable generic sildenafil tablets in healthy male	Clin Ther
ic diseases in six low- and middle-income countries	Bulletin of the World Health Organization
sector in different regions of Brazil]	Cad Saude Publica
Organization for Co-operation and Economic Development. 2007]	Salud Publica Mex
ico]	Cad Saude Publica
Biosimilars	Adv Rheumatol
	Curr Rheumatol Rep
opies of biologics in rheumatology	Rheumatol Int
	Clin Rheumatol
Brazil and South Africa: a comparative analysis	Global public health
atment: lessons from Brazil	Glob Public Health
se in an intensive care unit in Colombia	Braz J Infect Dis
	Lancet Oncol
ountries: issues and challenges	Aids
a of drug patent terms]	Cad Saude Publica
t safety and drug market dynamics in Brazil	Cien Saude Colet
es]	Rev Peru Med Exp Salud Publica
	Nat Med
ilars in Latin America: a point of view	Clin Rheumatol
	Antivir Ther
m	Rev Saude Publica
stry]	Cien Saude Colet
and Marketing Authorization of Biosimilar Medicines in BRICS-TM	Pharmaceut Med
With Australia, Canada and Switzerland: Benchmarking Best Practices	Front Pharmacol
s of BRICS-TM: Challenges and Opportunities	Front Med (Lausanne)
	Prep Biochem Biotechnol
an update of the Brazilian requirements	Aaps j
Department of Tamaulipas, Mexico]	Salud pública de México
the processes that led to the use of compulsory licensing in Thailand and	Dev World Bioeth
, international trade, and the right to health in Brazil and beyond	J Law Med Ethics
done	Cancer
nsiderations for clinicians in Latin America	MAbs
es of access to biological products in the Brazilian market	Einstein (Sao Paulo)
	Health Aff (Millwood)
es	Pharm Pat Anal
on, and current controversies on drug interchangeability	Medwave

Appendix Table S2 (continued)

**List of records excluded during screening and data extraction.**

	<b>Author</b>	<b>Year</b>	<b>Title</b>
623	Sweet, C. M.	2017	The Politics and Policies of Regulating Generics in Latin America: A Survey
624	Hoehn, E.	2002	TRIPS, pharmaceutical patents, and access to essential medicines: a long view
625	Teixeira, F. V., P. G. Kotze, A. O. Damião and S. J. Miszputen	2015	Biosimilars in inflammatory bowel diseases: an important moment for Brazil
626	Tieu, C., E. J. Lucas, M. DePaola, L. Rosman and G. C. Alexander	2018	Efficacy and safety of biosimilar insulins compared to their reference products
627	Tobar, F.	2008	[Economy of generic drugs in Latin America]
628	Vacca González, C. P., J. F. Fitzgerald and J. A. Bermúdez	2006	[Defining generic drugs: an end or a means? Analysis of regulations in Latin America]
629	Veras, J.	2014	Making tenofovir accessible in the Brazilian public health system: patent challenges
630	Vianna Araujo, D.	2012	Considerações Regulatórias sobre Produtos Biológicos em Brasil
631	Vieira, F. S. and P. Zucchi	2006	[Price differences between generic and innovator medicines in Brazil]
632	Vosgerau, M. Z., R. K. de Souza and D. A. Soares	2011	[Utilization of generics in an area covered by a family health unit in a southern city]
633	Wirtz, V. J., Y. Santa-Ana-Tellez, C. H. Trout and W. A. Kaplan	2012	Allocating scarce financial resources for HIV treatment: benchmarking priorities
634	Wogart, J. P. and G. Calcagnotto	2006	Brazil's fight against AIDS and its implications for global health governance
635	Xibille, D., S. Carrillo, G. Huerta-Sil, R. Hernández, L. Limón, G. Olvera-Soto, L. J. Jara-Quezada, A. Esquivel and M. Pérez-Rodríguez	2018	Current state of biosimilars in Mexico: The position of the Mexican College of Physicians
636	Azevedo, V. F., E. Sandorff, B. Siemak and R. J. Halbert	2012	Potential Regulatory and Commercial Environment for Biosimilars in Latin America
637	Monk, B. J., P. E. Lammers, T. Cartwright and I. Jacobs	2017	Barriers to the Access of Bevacizumab in Patients with Solid Tumors and their Implications
638	Guttier, M. C., M. P. T. Silveira, V. L. Luiza and A. D. Bertoldi	2017	Factors influencing the preference for purchasing generic drugs in a Southern Brazilian city
639	Not found	1999	[A program to detect deficient quality of commercialized drugs]
640	Not found	2001	Production of low cost AIDS drugs to continue in Brazil
641	Not found	2001	Brazil plans to make generic AIDS drugs
642	Not found	2001	... and Brazilian AIDS programme threatened by US trade action
643	Not found	2002	Brazil shares blueprint of successful battle against HIV/AIDS
644	Not found	2002	TAC, MSF import generic AIDS drugs into South Africa
645	Not found	2002	South Africa: defiance campaign continues
646	Not found	2005	[Input to the discussion on proposed regulation of prescription pharmacies]

	Journal
ey of Seventeen States	J Health Polit Policy Law
vay from Seattle to Doha	Chic J Int Law
zilian gastroenterologists	Arq Gastroenterol
ucts: A systematic review	PLoS One
	Rev Panam Salud Publica
ountries in the Region of the Americas]	Rev Panam Salud Publica
onflicts and generic production	Dev World Bioeth
	Value Health Reg Issues
	Rev Saude Publica
thern Brazilian city]	Rev Bras Epidemiol
ces of antiretroviral medicines in Latin America	Health Policy Plan
ce	Healthc Q
ge of Rheumatology, 2016	Reumatol Clin (Engl Ed)
n America	Value Health Reg Issues
the Potential Impact of Biosimilars: A Physician Survey	Pharmaceuticals (Basel)
ern Brazilian city	Rev Saude Publica
	Rev Panam Salud Publica
	Reprod Health Matters
	Nature
	Int J Epidemiol
	AIDS Policy Law
	IAPAC Mon
	Canadian HIV/AIDS policy & law review
]	Rev Saude Publica